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Abstract
The advent of molecular imaging as a discipline has drastically improved our ability to
understand the biochemical and cellular events that drive life, death and disease. This thesis
will document the discovery of new metal chelators for Re/99mTc, new methods of
incorporating these metals into peptide structures, as well as new fluorescent compounds.
These novel methods and compounds may be used in the development of molecular imaging
probes for single photon emission computed tomography (SPECT) and optical imaging
techniques, with applications for differentiating cancerous tissue from benign and healthy.
Chapter 2 discusses the development of a dual modality Re/99mTc imaging probe for
fluorescence/SPECT imaging for evaluating CXCR4 expression in cancer cells. The T140
derivative contains a 4-amino-1,8-naphthalimide chelator to bind rhenium or technetium-99m
for fluorescence or SPECT imaging. The rhenium coordinated peptide retained high affinity
for CXCR4 and was able to detect cells expressing the receptor by fluorescence microscopy.
However, little uptake of the technetium-99m labelled peptide was observed in CXCR4
expressing tumors in a murine model.
Chapter 3 aims to address the shortcomings of the naphthalimide chelation system discussed
in chapter 2. Three 4-amino-1,8-naphthalimides containing chelators with a positive, neutral
or negative charge were synthesized and coordinated with rhenium. All three complexes had
photophysical properties that were compatible with confocal fluorescence microscopy and
showed uptake in cells that was dependent on charge. All three ligands were radiolabelled with
technetium-99m in high radiochemical yield and purity.
Chapter 4 discusses the development of a b-hairpin forming peptide containing a 2,2’bipyridine moiety to chelate Re/99mTc. A novel amino acid based on 3,3’-diamino-2,2’bipyridine was synthesized, and incorporated into a peptide. Circular dichroism spectroscopy
indicated a lack of secondary structure, but formation of secondary structures resembling a bsheet was possible upon the addition of 2,2,2-trifluoroethanol (TFE). However, metal
coordination resulted in unstable complexes that were unable to be isolated.
i

Chapter 5 discusses the development of 2,2’-bipyridine-based fluorophores for the detection
of intracellular Zn(II). Two benzimidazole functionalized bipyridines were found to have a
fluorescence response to Zn(II) that was compatible for detection by confocal fluorescence
microscopy. Both ligands displayed fluorescence in benign prostate cells due to Zn(II)
coordination but not in prostate cancer cells. These ligands are promising candidates for the
detection of Zn(II) in ex vivo prostate tissues for differentiating malignant tissue from benign
and healthy.
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Introduction

1.1 Molecular Imaging
Living organisms are a complex medley of synergistic biochemical and cellular events, and
unveiling these processes that drive life, death and disease is a formidable task. In the past,
our progress towards this goal had been impaired by our inability to observe these
processes in living organisms as they occur, without perturbing the natural environment in
which they take place. The advent of molecular imaging as a discipline has drastically
improved our ability to understand these processes. While the precise definition of the term
molecular imaging may be different amongst various researchers and scientists, the
definition put forth by Gambhir & James will be used here: the non-invasive, real-time
visualization of biochemical processes at the cellular and molecular level within living
cells, tissues or organisms.1 Not only do molecular imaging techniques allow for
fundamental research into biochemical and cellular processes, they also have use in a
clinical setting, allowing for the diagnosis and monitoring of disease which can be used to
devise treatments that may preclude the need for invasive procedures such as biopsies.
Molecular imaging is an incredibly broad field that encompasses a number of imaging
modalities including, but not limited to: positron emission tomography (PET), single
photon emission computed tomography (SPECT), magnetic resonance imaging (MRI) and
optical fluorescence imaging (OI). Each of these imaging modalities has its own inherent
strengths and weaknesses in terms of molecular sensitivity and spatial resolution (Figure
1.1) as well as depth of tissue penetration and cost.2 Nuclear imaging modalities such as
PET and SPECT offer remarkable sensitivity and unlimited tissue penetration at the cost
of requiring ionizing radiation. MRI techniques do not require ionizing radiation but suffer
from low sensitivity. OI has limited clinical use due to the limited depth of tissue
penetration.
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Figure 1.1: Comparison of spatial resolution and molecular sensitivity between imaging
modalities.

1.2 Molecular Imaging Probes
Molecular imaging modalities often require a method to create a signal or image contrast
that is detectable by external detectors. In order for this signaling entity to reach the organs,
tissues or cellular compartments of interest it must be chemically attached to a targeting
entity that is able to interact with molecular targets in the region of interest. These
molecular targets may be receptors, transporters or enzymes. The combination of a
targeting entity and signaling entity for the purpose of molecular imaging is called a
molecular imaging probe, though other terms such as molecular imaging agent are often
used. Figure 1.2 depicts three examples of molecular imaging probes. Further details about
the targeting and signaling entities will be presented in this section.

1.2.1

Targeting Entity

The choice of targeting entity is critical, as this component can determine many of the
pharmacological properties of the molecular imaging agent. While it is difficult to predict
the pharmacokinetics of an imaging agent, it is widely acknowledged that molecular size,
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charge, lipophilicity and binding affinity to the target of interest are all contributing
factors.3–6 The most common targeting entities are derived from small molecules, peptides
or monoclonal antibodies (mAbs).

Figure 1.2: Examples of molecular imaging probes for PET ([18F]FDG), SPECT
([99mTc]Tc-HYNIC-TOC) and OI (RGD-Cy5.5).
Small molecules (usually <500 Da) typically offer good pharmacokinetic properties such
as fast accumulation in the target tissues, and quick clearance from the vasculature, giving
good signal-to-background contrast.1 However, due to their small size, they are often
limited in the type of signaling components that may be incorporated, as large fluorophores
and metal chelators can negatively impact the small molecule’s ability to bind to and reach
its target. On the opposite end of the spectrum, mAbs are typically on the size range of 150
kDa, and due to their large size, may be appended with large fluorophores and metal
chelators without affecting the incredibly high affinity and specificity that they have for
their molecular targets. However, mAbs have long biological half-lives (typically days to
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weeks) and are retained in the blood for long periods of time which can result in low signalto-background ratios, and therefore poor quality images.7 Peptides have found a place as
the “best of both worlds” between small molecules and mAbs. They offer the benefits of
small molecules such as membrane permeability and fast clearance kinetics, but retain the
high stability, target specificity and tolerance towards modification that mAbs possess.8,9
Peptides are also easily synthesized by solid-phase peptide synthesis, and are easily
modified to improve in vivo stability, pharmacokinetics and affinity for the molecular target
of interest.

1.2.2

Signaling Entity

A wide variety of signaling entities are available depending on the chosen imaging
modality. Optical imaging requires the addition of a fluorescent molecule to the targeting
entity. For in vitro cellular microscopy, fluorophores with emission wavelengths ranging
from 400-600 nm are most widely used such as fluorescein isothiocyanate (FITC), 7amino-4-methylcoumarin (AMC) and 5-carboxytetramethylrhodamine (TAMRA) (Figure
1.3, A-C). For in vivo imaging applications however, wavelengths in the near infrared
(NIR) window (650-900 nm) are required due to signal attenuation by tissues in the visible
range.10 Far-red cyanine dyes are the most commonly used fluorophores for this purpose.11
Various chemical methods such as amidation, thiourea formation, and click chemistry may
be used to conjugate fluorophores to targeting entities such as peptides and mAbs.12,13
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Figure 1.3: Structures of some common fluorophores (A-C), bifunctional chelators (D-F)
and prosthetic groups (G and H) used in signaling components of molecular imaging
probes. (A) Fluorescein isothiocyanate (FITC), (B) 7-amino-4-methylcoumarin (AMC),
(C) 5-carboxytetramethylrhodamine (TAMRA), (D) 1,4,7,10-tetraazacyclododecane1,4,7,10-tetraacetic acid (DOTA), (E) diethylenetriaminepentaacetic acid (DTPA), (F)
[bis(pyridine-2-ylmethyl)amino]acetic

acid

(BPA),

(G)

N-succinimidyl

[18F]4-

fluorobenzoate ([18F]SFB), (H) [11C]methyl iodide.
Four common strategies are employed for incorporating radioisotopes into targeting
molecules: pendant labelling, prosthetic group labelling, direct labelling and integrated
labelling (Figure 1.4).9 Pendant labelling is commonly employed with radiometals for
labelling of peptides and mAbs. This method involves the attachment of a bifunctional
chelator to the targeting entity in a location away from the biologically active site.
Examples of bifunctional chelators include 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid (DOTA), diethylenetriaminepentaacetic acid (DTPA), and [bis(pyridine-2ylmethyl)amino]acetic acid (BPA) (Figure 1.3, D-F). For a peptide, these chelators are
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typically connected to one of the termini, or an amino acid side-chain such as a lysine sidechain. Some examples of molecules labelled by this method include somatostatin
derivatives such as [99mTc]Tc-HYNIC-TOC14 and the CXCR4 targeting peptide [68Ga]GaPentixafor.15 This method can be problematic as it results in an increase in the molecular
weight and size of the molecule, and can affect binding to the target of interest. An
integrated labelling approach may be used to mitigate the effects of pendant labelling. This
method attempts to “hide” a radioisotope within the framework of the targeting entity, often
using a radiometal to induce the formation of secondary structure in a protein or peptide,
or stabilize already present secondary structures.16–18 An integrated approach has also been
employed in steroid mimics targeting the estrogen receptor.19–21 This approach of
concealing the radioisotope would ideally have little effect on the affinity of the targeting
entity to the molecular target. Radionuclides such as

18

F and

11

C are most commonly

incorporated into imaging agents through the prosthetic group labelling approach. This
involves the radiolabelling of a small molecule “prosthetic group” containing a reactive
group which may then be conjugated to the targeting entities. N-succinimidyl [18F]4fluorobenzoate ([18F]SFB)22 and [11C]methyl iodide23 (Figure 1.3, G and H) are common
prosthetic groups employed for radiolabelling of peptides, proteins and small molecules.
Direct labelling approaches are typically involved in the radiosynthesis of small molecules
such as [18F]2-fluoro-2-deoxyglucose ([18F]FDG),24 where a leaving group is directly
displaced with the radionuclide. There are however, several published methods for the
direct labelling of peptides and other biomolecules.25–27
A wide range of methodologies are available for combining a signaling entity with a
targeting entity for the creation of molecular imaging probes. The choice of method
strongly depends on the molecular target of interest, the desired pharmacokinetic
properties, and the available ligands that can bind to the molecular target.
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Figure 1.4: Methods for incorporating a radioisotope into PET and SPECT molecular
imaging probes. Pendant and integrated methods are often employed when using
radiometals such as

68

Ga and

99m

Tc, while prosthetic group and direct labelling are

employed with non-metal radioisotopes such as 11C and 18F.

1.3 Single Photon Emission Computed Tomography
Single photon emission computed tomography (SPECT) imaging is the most widely used
imaging modality in nuclear medicine due to the availability of on-site generators to
produce the required radionuclides. Gamma-emitting radionuclides such as 99mTc (t1/2 = 6
hrs),

111

In (t1/2 = 2.8 days) and 123I (t1/2 = 13.2 hrs) are employed for this modality. Their

decay energies, which range from 100 to 300 keV, are optimal for tissue penetration, while
being relatively innocuous to the subject.28 These isotopes are typically produced in an onsite generator or by a cyclotron. SPECT radioisotopes tend to be longer lived than PET
radioisotopes, with half-lives ranging from 6 hours to 3 days.9 This is sufficient time for
radiosynthesis, purification and administration to patients, followed by biodistribution and
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imaging. The longer half-lives of SPECT isotopes also provide the opportunity for imaging
over longer periods of time.
Gamma-emitting isotopes produce gamma-rays unidirectionally, requiring the detector (a
gamma camera) to be rotated around the subject, collecting images from multiple angles
for 3D reconstruction. Signal attenuation is a common problem in SPECT, as collimators
are required to exclude gamma rays that have been scattered. This results in lower
sensitivity than PET, and makes quantitative information nearly impossible to gather.29,30
Despite these shortcomings, SPECT imaging is an integral technique in nuclear medicine
due to its wide availability, and relatively low cost.

1.4 Technetium-99m
Technetium-99m is considered a workhorse radionuclide in nuclear medicine. In the late
1990s to early 2000s, it accounted for approximately 80% of radiopharmaceuticals used
clinically and 85% of diagnostic nuclear imaging procedures in hospitals.31,32 Technetium99m emits gamma rays with a decay energy of 140 keV, which is considered optimal for
imaging with gamma cameras, and has a half-life of 6 hours. This half-life is long enough
for preparation and administration of the imaging agent, while minimizing the absorbed
radiation dose. Technetium-99m is typically produced by radioactive decay of
molybdenum-99 in a generator system.33,34 In recent years, cyclotron production of
technetium-99m has been explored as an alternative.35 From the more common generator
system, molybdenum-99 decays by b- decay (t1/2 = 66 h) to technetium-99m. This
metastable nuclear isomer decays to the ground state technetium-99 predominantly by
emission of a 140 keV gamma ray. Technetium-99 subsequently decays with an
exceptionally long half-life of 2.12 x 105 years to the stable ruthenium-99 by b- decay
(Figure 1.5).
The technetium-99m is eluted from a

99

Mo/99mTc generator in the form of sodium

pertechnetate ([99mTc]NaTcO4), where the technetium is in the synthetically inaccessible
+7 oxidation state and must be reduced to a lower oxidation state for incorporation into
radiopharmaceuticals. Oxidation states ranging from -1 to +7 are accessible for technetium,
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though for medical applications the +1, +3 and +5 oxidation states are used most
commonly.36

Figure 1.5: Radioactive decay scheme of 99Mo to the stable isotope 99Ru.
Technetium-99m radiopharmaceuticals can be classified into two categories: “99mTcessential” and “99mTc-tagged” radiopharmaceuticals. In the former, the technetium-99m is
an integral component of the radiopharmaceutical. Neither the technetium-99m nor the
ligand on its own can reach the target of interest, only after metal coordination to the ligand
does the agent have the desired pharmacological properties. Perfusion agents such as
[99mTc]Tc-MAG337 and [99mTc]-Sestamibi38 are classical examples of “99mTc-essential”
radiopharmaceuticals (Figure 1.6, Top). 99mTc-labelled molecular imaging probes labelled
through the integrated method may be considered as “99mTc-essential” as well.
“99mTc-tagged” radiopharmaceuticals are in the same vein as pendant labelled molecular
imaging probes, where a bifunctional chelator is conjugated to a targeting entity that guides
the radioisotope to the molecular target of interest. [99mTc]Tc-HYNIC-TOC,14
[99mTc]TROD-AT-139 and [99mTc]Tc(CO)3(MIP-1404)40 (Figure 1.6, Bottom) are some
notable

examples

of

“99mTc-tagged”

radiopharmaceuticals.

radiopharmaceuticals commonly contain metal complexes with

99m

“99mTc-tagged”

Tc in the +3 or +5
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oxidation states due to their ease of labelling and purification, as well as the availability of
kit formulations.

Figure 1.6: Examples of “99mTc-essential” and “99mTc-tagged” radiopharmaceuticals.
Many of these complexes however, suffer from low stability in solution and in vivo41,42 or
contain multiple isomeric forms that may differ in their biological activity.43 In the late
1990’s Schubiger et al developed the fac-technetium(I) tricarbonyl core as an alternative.44
fac-[Tc(H2O)3(CO)3]+ was produced in a single step from NaTcO4 by reduction with
NaBH4 in aqueous solution under CO atmosphere. Other reagent systems have been
developed that do not require reaction under CO atmosphere and are therefore more
suitable for the synthesis of radiopharmaceuticals in a clinical setting.45 fac[Tc(H2O)3(CO)3]+ was demonstrated to be stable in aqueous solution at a pH range from 1
to 13 for several hours, and the water ligands were shown to be quite labile, allowing for
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substitution with tridentate ligands to form complexes with exceptional stability (>48 hours
in serum). This opened the doors for the development of a wide range of methodologies
for the incorporation of 99mTc into imaging probes (Figure 1.7).46–50

Figure 1.7:

99m

Tc(I)-tricarbonyl complexes formed with a wide variety of ligands.

Examples include tridentate ligands such as the amino acid histidine, cyclopentadienyl
ligands coordinated in an h3 fashion, and [2+1] systems where a bidentate and monodentate
ligand occupy the 3 coordination sites.
The high stability and facial orientation of the carbonyl ligands can be attributed to the
two-component bonding of the ligand to the metal center (Figure 1.8). The first component
is a simple sigma bond where the electrons in the sp-orbital of the carbon atom of the triple
bonded carbonyl ligand is donated to a vacant d-orbital on the metal. The second
component is a p back-bond. The partially filled d-orbital of the metal center can donate
electron density to the empty p* orbital of the carbonyl ligand. While this decreases the
CO bond order, the metal-CO bond order is increased, resulting in a strong metal-ligand
bond. The facial orientation results from the orientation of the d-orbitals that are backbonding to the carbonyl ligands.
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Figure 1.8: Two-component binding of a carbonyl ligand to a metal center.

1.5 Rhenium
As described in the previous section, the chemistry of technetium is vast, with a variety of
oxidation

states

and

ligands

available.

The

development

of

99m

Tc-labelled

radiopharmaceuticals can be challenging, as technetium has no stable isotopes. While
technetium-99 complexes may be produced on milligram to gram scales to study the
macroscopic properties of the technetium-99m complexes, the radioactive nature of the
isotope limits its availability and use. A more common approach is to use the nonradioactive rhenium as a surrogate for technetium. As both are group VII elements, they
share similar chemical reactivity, and tend to form isostructural complexes with similar
physicochemical properties such as size and lipophilicity.51 This allows not only for
structural characterization of the metal complexes by standard spectroscopic methods such
as X-ray crystallography and infrared spectroscopy, but also allows for in vitro evaluation
of

99m

Tc radiopharmaceuticals for their ability to bind a molecular target without the use

of radioactive material. Rhenium exists in nature as a mixture of two isotopes, 185Re (37%)
and 187Re (63%). Radioactive isotopes of rhenium 186Re and 188Re undergo b- decay, and
have seen clinical use as radiotherapeutics.52,53
Though rhenium has seen wide use as a surrogate for technetium-99m in the development
of radiopharmaceuticals, rhenium complexes are also useful in other aspects. Many Re(I)tricarbonyl complexes display photoluminescence properties and have been developed as
cellular imaging agents for microscopy applications (Figure 1.9).48,49,54–56 While these
photoluminescence properties generally result from metal-to-ligand charge transfer
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(MLCT) electronic transitions, complexation to rhenium has also been shown to modulate
the fluorescence properties of fluorophores adjacent to the metal complex.57,58
Luminescent Re(I)-tricarbonyl complexes typically have large Stokes shifts, long
luminescent lifetimes, high photostability and high cellular permeability, making them
ideal imaging agents for cellular microscopy. They also have the potential to aid in the
preclinical development of

99m

Tc radiopharmaceuticals by allowing the visualization of

tissue uptake and cellular localization of targeted imaging agents without the need for using
radioactive isotopes. They may also be helpful in the analysis of ex vivo tissue samples for
studying and diagnosing disease.

Figure 1.9: Examples of luminescent Re(I)-tricarbonyl complexes with p-accepting
polypyridyl ligands. Suitable ligands include 2,2’-bipyridine, phenanthroline, quinoline
and phenanthrodine.

1.6 C-X-C Chemokine Receptor 4
The C-X-C chemokine receptor 4 (CXCR4, also called LESTR or Fusin), a G proteincoupled receptor (GPCR), was originally discovered as a co-receptor to CD4 for HIV-1
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infection into T-lymphocytes.59–63 In addition to T-lymphocytes, it was also shown to be
expressed on B-cells and monocytes.60 The only known natural ligand to CXCR4, stromal
cell-derived factor 1 (SDF-1a, also called CXCL12) has been shown to support the
proliferation of B-cells64 and is a strong chemoattractant for lymphocytes and monocytes,
due to the interaction of SDF-1a with CXCR4.65 Together, CXCR4 and SDF-1a also play
a role in the recruitment of T-lymphocytes to sites of infection and inflammation within
the body,66,67 hematopoiesis,68 and embryonic development.69 In recent years, there has
been a surge in research on CXCR4/SDF-1a focusing on their role in cancer. CXCR4 is
expressed in at least 23 different types of cancer including breast, prostate, lung, colon,
glioma and multiple myeloma.70–77 Expression of CXCR4 in cancers has been shown to
promote metastasis,78–81 particularly to sites containing high expression of SDF-1a such as
lymph nodes, bone marrow, lungs and liver.71,82–85 Most healthy tissues contain very low
expression of CXCR4, but in cancerous tissue the expression is greatly enhanced. It may
also be noted, that while prostate cancer tissue overexpresses CXCR4, expression remains
low in benign prostatic hyperplasia (BPH) and healthy prostate tissue.86 This provides a
diagnostic biomarker that may be used to differentiate healthy and benign tissue from
malignant. The roles of CXCR4/SDF-1a in diseases such as cancer and HIV prompted the
development of inhibitors as therapeutics and molecular imaging agents for evaluation of
CXCR4 expression in vivo.
A turning point in the development of CXCR4 inhibitors occurred upon the discovery of
the antimicrobial self-defense peptides tachyplesin I & II and polyphemusin I & II from
the hemocytes of the horseshoe crabs Tachypleus tridentatus and Limulus polyphemus.87,88
These peptides are structurally intriguing as they contain 17 or 18 amino acids for
tachyplesin and polyphemusin respectively, an amidated C-terminus, and two disulfide
bridges stabilizing an anti-parallel b-sheet structure. Not only did these peptides
demonstrate antimicrobial activity, but were also shown to inhibit the infectivity of HIV-1
into MT-4 cells.89 Though they were effective at inhibiting HIV-1 infection, they were also
found to be relatively cytotoxic. As polyphemusin II was shown to have the greatest
inhibitory effect on HIV, it was used as a scaffold to reduce cytotoxic effects and improve
potency, which led to the development of the peptide T22 ([Tyr5,12, Lys7]-polyphemusin
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II), which had much greater potency, and reduced cytotoxicity.90,91 It wasn’t until 5 years
after the development of T22 that it was discovered the inhibitory effect on HIV was due
to the peptide’s interaction with CXCR4.92 Further efforts to reduce the molecular size of
the peptide while retaining high potency and low cytotoxicity resulted in the peptide TW70,
which reduced the size of the peptide to 14 amino acids, and removed one of the disulfide
bridges while retaining the b-sheet structure and potency, and reducing cytotoxicity.93 It
was observed that cell membrane permeability and the number of positive charges had a
great effect on the selectivity index (SI, ratio of cytotoxicity measure (CC50) to potency
(EC50)), resulting in the peptides T134, and finally T140, which replaced the amidated Cterminus with a carboxylic acid, and reduced the charge of the molecule to +7, giving the
highest SI values thus far.94,95 Figure 1.10 highlights the structural changes made from
polyphemusin II to T140.

Figure 1.10: The development of T140 from polyphemusin II. Black bars indicate
disulfide bridges (top bars pertain to polyphemusin II and T22, bottom bar pertains to
TW70, T134 and T140), colours indicate structural changes made in the subsequent
peptide.
Alanine scans of T140 determined that there were 4 residues that were indispensable to the
binding affinity of the peptide to CXCR4: Arg2, Nal3, Tyr5 and Arg14.95 This eventually led
to the development of the cyclic pentapeptide FC131 (cyclo[Nal1-Gly2-D-Tyr3-Arg4Arg5]), which retained similar affinity for CXCR4 as T140.96
Small molecule CXCR4 inhibitors have also been developed separately from the peptide
inhibitors. It was noticed that molecules containing two cyclam rings (bicyclams) were
able to inhibit HIV infection in human T cells with varying potencies, without any
noticeable cytotoxic effects.97 It was eventually determined that a p-xylylene spacer linking
the two cyclam rings gave the compound with the highest potency out of all of the
synthesized analogues, and was denoted JM3100.98 This compound now goes by the name
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AMD3100 or Plerixafor, and it has been shown to inhibit HIV infection through interaction
with CXCR4.99 AMD3100 has also seen clinical use as a mobilizer of hematopoietic stem
cells.100 Figure 1.11 depicts the structures of the described CXCR4 inhibitors T140, FC131
and AMD3100.

Figure 1.11: Peptide (T140, FC131) and small molecule (AMD3100) inhibitors of
CXCR4.
While CXCR4 inhibitors show great promise as therapeutics for HIV, they have also shown
potential as anti-metastatic agents in several cancers.101,102 The ability to target CXCR4 in
cancer has garnered much interest in developing molecular imaging agents containing
radioactive and fluorescent tags for evaluation of CXCR4 expression both in tissue
samples, and in vivo. As healthy tissue surrounding the diseased site does not express high
amounts of CXCR4, the diseased tissue may be specifically targeted by molecular imaging
agents. Figure 1.12 depicts the structures of several radiolabelled molecular imaging agents
targeting CXCR4. A wide range of T140 derivatives have been developed containing
imaging labels. These labels are typically placed on the peptide’s N-terminus, or from the
D-Lys side chain. It has been demonstrated that the turn region lies outside of the CXCR4

binding pocket, making the D-Lys side chain ideal for conjugation of an imaging moiety.103
Amidation of the N-terminus has also been shown to have little effect on binding affinity,
often improving it, though bulky substituents may have negative effects on receptor
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binding. The first reported PET imaging agent based on the T140 scaffold was [18F]4-FBTN14003 (Figure 1.12, Top Right).104 This peptide contains an [18F]4-fluorobenzoyl
([18F]4-FB) group on the N-terminus, which improved CXCR4 affinity for the receptor.
However, addition of the 4-FB group had the unwanted side effect of causing non-specific
binding to red blood cells, which made targeting CXCR4 expressing tumors rather
challenging in vivo. Inclusion of a non-radioactive, fluorine-19 containing N-terminal 4FB group in other radiolabelled T140 derivatives showed similarly high blood uptake in in
vivo animal models.105 Several other radiolabelled T140 derivatives have mitigated the
problem of binding to blood cells, but often give poor tumor uptake or high accumulation
in the liver and kidneys.106–108 Despite the shortcomings of these agents, a 68Ga-labelled
T140 derivative has been tested for imaging of CXCR4 expression in glioma patients.109
This imaging agent showed specific uptake of the tracer in the cancerous tissue, with a
much lower background signal in comparison to [18F]FDG. Fluorescently labelled T140
derivatives have been used successfully as an alternative to antibody staining to evaluate
CXCR4 expression in Ewing sarcoma110 and high-grade bladder cancer.111

Figure 1.12: PET and SPECT molecular imaging agents targeting CXCR4.
Structure-activity relationship studies on FC131 led to the development of the Pentixafor
(previously named CPCR4-2) scaffold (Figure 1.12).112,113 Coordination of Ga(III) to the
appended DOTA chelator resulted in an imaging probe with similar affinity to CXCR4 as
FC131. The

68

Ga-labelled peptide has been used in humans for imaging of CXCR4
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expression in a wide variety of cancers, and has great promise as a clinically useful PET
imaging agent.15,114,115 Several other derivatives of Pentixafor have been explored in in
vitro models, and also show promise for in vivo imaging as well as radiotherapy.116–119 It
was previously demonstrated that coordination of AMD3100 with metal ions such as
Cu(II), Zn(II) and Ni(II) improved the binding affinity of the molecule to CXCR4.120 This
concept has been used in the development of radiolabelled AMD3100 analogues.
[64Cu]Cu-AMD3100 was used to successfully differentiate CXCR4-positive tumors in an
in vivo animal model.121,122 99mTc-labelled AMD3100, and the derivative AMD3465 have
also shown promise as SPECT imaging agents for imaging of CXCR4 expressing tumors
in vivo.123,124
Targeting of the CXCR4/SDF-1a axis for therapeutic and diagnostic purposes in HIV and
cancer is a large and rapidly growing field. Despite all of the work in the field, the need for
imaging agents with improved pharmacokinetic and biodistribution profiles is still an area
of research that is actively being developed. While radiolabelled agents targeting CXCR4
are being evaluated in humans for PET imaging, there is still a need for imaging agents
compatible with SPECT imaging, as well as PET agents with improved pharmacokinetics.

1.7 Biological Roles of Zinc
Zinc is a ubiquitous element in the human body. It is the second most abundant transition
metal, second only to iron. Under physiological conditions, zinc is found in the form of
Zn(II). While total zinc concentration in cells is in the mM range, free zinc concentrations
are tightly regulated. This is achieved through active transport by the zinc transporter (ZnT)
and zrt-like, irt-like protein (ZIP) classes of transporters,125 buffering of zinc by
metallothioneins,126 and sequestering of zinc into organelles such as zincosomes.127,128 This
results in free zinc concentrations in the nM range.129
Zinc has a broad range of cellular functions and roles (Figure 1.13). Zn(II) ions function as
co-factors for a number of zinc-dependent enzymes.130–132 Enzymes such as carbonic
anhydrase,133 carboxypeptidase A,134 and alkaline phosphatase135 require the Zn(II) ion to
activate electrophilic sites so that enzymatic hydrolysis can occur. Zn(II) ions act as
structural elements of many proteins such as zinc finger transcription factors.136 Insulin is
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also stored as a hexamer through coordination with Zn(II),137 and metal ions such as Zn(II)
and Cu(II) have been implicated in the formation of amyloid plaques in Alzheimer’s
disease.138 Zn(II) signaling plays a key role in neurotransmission,139,140 as well as the
activation and inhibition of transcription factors.141 Disruption of the tightly regulated zinc
homeostasis has been implicated in a number of diseases such as diabetes,142 Alzheimer’s
disease138 and prostate cancer.143 The following section will discuss the role of zinc in the
latter.

Figure 1.13: Biological distribution and functions of zinc. Abbreviations: IAP, inhibitor
of apoptosis protein; ROS, reactive oxygen species; ER, endoplasmic reticulum; ZIP, Zrtlike, Irt-like protein; ZnT, zinc transporter.

1.7.1

Zinc in Prostate Cancer

It was documented as early as the 1920s that the human prostate has the highest zinc
concentration of any soft tissue (~1000 µg/g of dry tissue),144 though the exact reason for
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this is not entirely clear. It has been noted that prostate epithelial cells have
characteristically high aerobic glycolysis, low respiration rates, and high citrate secretion,
and it has been proposed that high zinc concentrations are required to maintain these
characteristics.145,146 Zinc was shown to inhibit m-aconitase, an enzyme responsible for
citrate oxidation, which may be responsible for the high citrate secretion and low
respiration in prostate tissue.147,148 It has also been demonstrated that in malignant prostate
tissue there is a nearly ten-fold reduction in zinc concentration.149 Decreases in cellular
zinc may lead to an increase in cellular respiration favouring growth and differentiation,
which may lead to malignancy.150 Zinc has also been shown to regulate apoptosis in
prostate cells.151 Lower levels of zinc can be attributed to an increase in the expression of
ZnT proteins, responsible for zinc export, and a decrease in the expression of ZIP proteins,
which are responsible for zinc import.152 Also to be noted, benign hyperplastic prostate
tissue retains the high zinc accumulation observed in healthy prostate tissue.149
Due to the characteristic decrease in zinc concentration in malignant prostate tissue, there
has been much clinical interest in zinc as a biomarker for prostate cancer, allowing for the
differentiation of malignant prostate tissue from benign and healthy. Evaluation of prostatic
zinc levels has mostly been limited to ex vivo analysis of biopsies through a variety of
methods.153–155 More recently, the development of molecular imaging agents for in vivo
analysis of prostatic zinc levels has been investigated.156 However, for the pre-clinical
study of zinc as it relates to disease, the development of fluorescent, cell permeable
indicators for zinc has been a large area of investigation.157,158 The following section will
discuss the mechanisms behind the function of zinc-sensitive fluorescent probes.

1.7.2

Fluorescent Probes Responsive to Zinc

The detection of zinc by spectroscopic methods can be challenging, as the 3d10 electron
configuration makes the metal ion alone insensitive to spectroscopic methods such as NMR
and UV/Vis. However, ligand-centric photophysical processes may be exploited as a
method of fluorescence detection of Zn(II). Quantum yields, fluorescence lifetimes, and
excitation/emission energies of a ligand/fluorophore can be manipulated by coordination
to Zn(II). The appropriate choice of chelator and fluorophore that imparts selectivity to
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Zn(II) over other metal ions would give a fluorescent probe with a signal unique to the
presence of Zn(II).
Fluorescent stains for biological zinc began gaining wide acceptance in the 1980s with
histochemical stains based on 8-aminoquinoline such as N-(6-methoxyquinolin-8-yl)-ptoluenesulfonamide (TSQ).159 Further research has focused on improving cellular
permeability160 and shifting excitation and emission wavelengths further into the visible
range (Figure 1.14).161

Figure 1.14: Evolution of zinc responsive fluorescent probes: TSQ, to the more cell
membrane permeable ZnAF-R2, and the visible light excitable FluoZin-1, and the cell
membrane permeable variant FluoZin-1 AM.
A variety of ligand-centric photophysical processes have been exploited in the
development of zinc-responsive fluorescent probes. These include: photoinduced electron
transfer (PeT), intramolecular charge transfer (ICT), excited-state intramolecular proton
transfer (ESIPT), Förster resonance energy transfer (FRET), and excimer/exciplex
formation. In this section, PeT, ICT and ESIPT will be discussed in further detail.
Photoinduced electron transfer (PeT, not to be confused with positron emission
tomography (PET)) is a fluorescence quenching mechanism that occurs in molecules
containing a fluorophore that is appended with an electron donor. Note that there is no
conjugated p-system involved (i.e. there is no ground state mixing of the respective
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molecular orbitals). Upon promotion of the fluorophore to the excited state, the electron
donor may donate an electron into the half-filled HOMO of the fluorophore (a redox
process), affording a radical cation/anion pair. This prevents the electron located in the
LUMO of the fluorophore from returning to the ground state, effectively quenching
fluorescence emission. As PeT applies to Zn(II) indicators, the electron donor is typically
a chelating moiety, capable of selectively binding to Zn(II). Chelators containing tertiary
amino groups are often employed due to their oxidizable nature. The HOMO of the chelator
is of a higher energy than that of the fluorophore, allowing for donation of an electron from
the chelator to the fluorophore. In the free ligand state, fluorescence is efficiently quenched
(Figure 1.15, Top).
However, coordination of the chelating moiety to Zn(II) lowers the HOMO energy of the
electron donor, preventing electron transfer to the excited state fluorophore HOMO. This
restores the fluorescence emission pathway (Figure 1.15, Bottom). PeT sensors are
therefore “turn-on” sensors. Coordination to Zn(II) typically causes little change in the
excitation and emission energies, but an increase in fluorescence quantum yield (ff) is
observed. The fluorescence intensity may then be correlated to the concentration of Zn(II).
FluoZin-1 (Figure 1.14, right) is an example of a Zn(II) indicator operating by a PeT
mechanism.
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Figure 1.15: The process of PeT as applied to Zn(II) indicators. Coordination of Zn(II)
prevents the metal chelator from acting as an electron donor, increasing fluorescence
intensity from the fluorophore.
In contrast to PeT where an electron donor and acceptor are separated, ICT fluorophores
contain a p-conjugated electron donor and acceptor. Upon photoexcitation, charge
separation occurs in the fluorophore, resulting in a polar excited state. Fluorophores
displaying ICT characteristics are positively solvatochromic in nature (i.e. excitation and
emission energies decrease with increasing solvent polarity). In non-polar solvents, a
“locally excited” state occurs in which the excited fluorophore has little effect on solvent
ordering. In polar solvents, the solvent molecules may align their dipoles with the dipole
of the excited fluorophore, effectively decreasing the energy of the excited state, and
shifting the fluorescence emission wavelength further into the visible range (Figure 1.16,
Top).162
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Figure 1.16: ICT mechanism in non-polar and polar solvents (top), and upon coordination
to Zn(II) (bottom).
In the case of the zinc indicator ZnAF-R2 (Figure 1.14, middle) where Zn(II) binds to the
electron donor site, the ability of the donor to transfer electron density to the acceptor is
reduced and the excited state is destabilized, which hypsochromically shifts the excitation
and emission wavelengths. However, coordination of Zn(II) to the acceptor site, as is the
case in many 2,2’-bipyridine based zinc indicators, results in a stabilization and a decrease
in polarity of the excited state due to the cationic Zn(II) (Figure 1.16, Bottom). As a result,
a bathochromic shift in the excitation and emission wavelengths occurs. As the free ligand
and the Zn(II) complex will typically display fluorescence, in theory the ratio of the
fluorescence emission from the ligand and the Zn(II) complex may be used to determine
Zn(II) concentrations. This is usually not done in practice however, as the absorption
wavelengths of the free ligands often occur in the UV range, and are not ideal for use in
live cells and tissues.
ESIPT occurs in molecules where intramolecular hydrogen bonds are present, and
tautomerization is possible.163 Phototautomerization may occur in the excited state of a
molecule, with a concomitant transfer of a proton from a photoacid to a photobase. 2-(2’Hydroxyphenyl)benzoxazole (HBO) is an example of an ESIPT fluorophore (Figure 1.17).
In non-polar solvents, ESIPT occurs at a faster rate than fluorescence emission. Therefore,
the lower energy emission from the phototautomeric form dominates. As solvent polarity
increases, the rate of proton transfer decreases due to hydrogen bonding with the solvent,
and the emission from the phototautomer decreases. If the photobasic and photoacidic sites
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become coordinated to a metal ion such as Zn(II), ESIPT is no longer possible (Figure 1.17,
Left). The emission energy becomes intermediate between the energies of the
phototautomeric forms. As with ICT fluorophores, the ratio between emission from the
free ligand and the metal complex may be used to determine Zn(II) concentrations.

Figure 1.17: Process of ESIPT occurring in HBO, and Zn(II) coordination suppressing
ESIPT.
While there is certainly a plethora of Zn(II) sensitive fluorescent probes to choose from,
there is still plenty of room for advancement in the field. There is still a need to develop
sensors with useful ratiometric fluorescence emission, so that the probe may be visualized
in the free ligand, and Zn(II) coordinated states, improvement in cellular permeability and
cellular localization as well as a lack of toxicity to the target cells or tissues that are being
interrogated.164

1.8 Summary
This thesis will document the discovery of new metal chelators for Re/99mTc, new methods
of incorporating these metals into peptide structures, as well as new fluorescent
compounds. These novel methods and compounds may be used in the development of
molecular imaging probes for SPECT and OI techniques, with applications for
differentiating cancerous tissue from benign and healthy. Chapter 2 will discuss the
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development of a dual modality Re/99mTc imaging probe for fluorescence/SPECT imaging
derived from T140 for the evaluation of CXCR4 expression in cancer cells, with
applications to differentiating malignant prostate cells from benign. Chapter 3 contains a
study evaluating the fluorescence properties and radiolabelling of Re/99mTc-containing 4amino-1,8-naphthalimides towards tuning the pharmacokinetic and biodistribution
properties of their bioconjugates. Chapter 4 highlights the challenges in developing
integrated molecular imaging probes. The development of 3,3’-diamino-2,2’-bipyridine
containing peptides as SPECT imaging agents will be discussed. Chapter 5 will discuss the
development of amino-substituted 2,2’-bipyridine ligands as intracellular Zn(II) sensors,
and their application in differentiating malignant and benign prostate cells by their
differences in Zn(II) uptake. Chapter 6 will summarize the findings of the thesis and how
they advance the field of molecular imaging as a whole.
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Chapter 2

2

A Dual Modality 99mTc/Re(I)-Labelled T140 Analogue for
Imaging of CXCR4 Expression

2.1 Introduction
The C-X-C chemokine receptor 4 (CXCR4) and its natural ligand CXCL12 are involved
in developmental, immune and inflammatory processes in healthy tissues.1,2 It was first
discovered as a co-receptor for HIV infection into T lymphocytes.3–5 CXCR4 has been
shown to be overexpressed in at least 23 types of cancer,6 including prostate cancer (PCa),7
where it and CXCL12 are involved in metastasis,7–9 angiogenesis,10 and adhesion of PCa
cells to bone marrow endothelial cells.11,12 While CXCR4 expression is higher in PCa and
associated metastases, expression is low in benign prostatic hyperplasia and normal
prostate tissue.13 This gives the potential for CXCR4 to be a biomarker to aid in the
diagnosis of PCa and differentiating malignant and benign tissue. CXCR4 expression was
shown to be a superior predictor of bone metastasis to the Gleason score, and that 94% of
patients with metastatic prostate cancer showed expression of the protein. Patients with
high CXCR4 expression had an overall lower cancer-specific survival than those with low
expression of the receptor.8 Therefore, CXCR4 is a potential diagnostic and prognostic
factor for prostate cancer. CXCR4 targeted imaging agents may aid in the visualization of
metastatic lesions, and CXCR4 antagonists have therapeutic potential for metastatic
prostate cancer.
Several CXCR4 antagonists have been reported, including the biscyclam AMD3100,14 14
amino-acid b-hairpin peptide T140,15 and cyclic pentapeptide FC131.16 These three
compounds have been widely used as scaffolds for the development of positron emission
tomography (PET), single photon emission computed tomography (SPECT), and
fluorescence imaging probes targeting CXCR4, and several published reviews discuss this
topic.17–19 While the development of CXCR4 targeted nuclear imaging probes has
previously been focused on PET agents containing 68Ga, 64Cu and 18F, only a few SPECT
imaging agents had been developed. Recently there has been a surge in the number of
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publications on CXCR4 targeted SPECT imaging agents containing

99m

Tc as the

radionuclide.20–23
Multi-modality imaging agents are of great interest, as a single compound may be used for
various clinical applications and can combine the advantages of different modalities, while
mitigating some of the disadvantages.24–26 These agents typically contain a separate label
for each modality (i.e. a radionuclide for PET/SPECT, and a fluorophore for fluorescence).
This presents many design challenges, as fluorophores and metal chelators can be quite
large in size and molecular weight. Conjugation of multiple large moieties to biomolecules
such as peptides can have a negative impact on their ability to bind a biological target. For
example, a dual-modality CXCR4 targeted imaging agent has previously been reported for
dual SPECT/fluorescence imaging.27 The T140 analogue Ac-TZ14011 was derivatized
with an 111In labelled diethylenetriaminepentaacetate (DTPA) chelator for SPECT imaging
and a Cy5.5 dye for fluorescence imaging. Introduction of these large moieties resulted in
a 20-fold reduction in binding affinity to CXCR4 due to increased steric bulk. Due to this
decrease in binding affinity, it would therefore be advantageous to reduce the size of the
appended labels by incorporating a fluorophore and radioisotope into a single, more
compact entity.28 Rhenium(I) tricarbonyl complexes can exhibit fluorescence and replacing
rhenium with technetium-99m would allow for single photon emission computed
tomography (SPECT) imaging. 4-Amino-1,8-naphthalimides appended with a di-(2picolyl)amine binding unit coordinated to Re(I) have been reported as cellular imaging
agents with ideal fluorescence properties.29 However, their incorporation into biological
molecules and labelling with 99mTc has not been explored.
Herein, we report the synthesis and evaluation of a dual modality imaging agent derived
from T140 containing a 4-amino-1,8-naphthalimide appended with a di-(2-picolyl)amine
(DPA) binding unit (Figure 2.1). The peptide was coordinated to Re(I) for evaluation of
CXCR4 binding and photophysical properties. CXCR4 expression in various cell lines,
including prostate cell lines, was observed by confocal fluorescence microscopy. Labelling
with 99mTc(I) was performed for evaluation in a murine xenograft model.
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Figure 2.18: Structure of T140 (6) and the newly synthesized derivative DPA-NaphT140 (7).

2.2 Results and Discussion
2.2.1

Design and Synthesis

A carboxylic acid functionalized dipicolylamine-naphthalimide (DPA-Naph) fluorophore
(5) was synthesized in five steps from commercially available 4-chloro-1,8-naphthalic
anhydride (scheme 2.1) and conjugated to T140 through solid-phase peptide synthesis.
Naphthalimide 1 was synthesized by reacting 4-chloro-1,8-naphthalic anhydride and ethyl
3-aminopropionate in refluxing ethanol. This was then heated in DMSO with tert-butyl (2aminoethyl)carbamate giving the Boc-protected amine 2. Deprotection of the Boc group
with TFA yielded the free amine 3, which underwent reductive alkylation with 2pyridinecarboxaldehyde to form the tridentate chelator 4. Saponification of the ethyl ester
gave the carboxylic acid 5 (DPA-Naph-OH), which could then be conjugated to a peptide
by standard peptide coupling methods.
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Scheme 2.1: Synthesis of compound 5 (DPA-Naph-OH).
The D-Lys8 side chain of T140 was chosen as the site of conjugation, as previous reports
show that this residue is located outside of the CXCR4 binding pocket.30 Peptides were
synthesized by standard Fmoc solid-phase peptide synthesis techniques. The D-Lys8 side
chain was protected with an allyloxycarbonyl (Alloc) protecting group for selective
deprotection and coupling of 5. Compound 5 was conjugated to the peptide through
standard HCTU coupling procedures. After disulfide bridge formation by oxidation with I2
and final Fmoc deprotection, the peptide was cleaved from the resin and purified by
preparative HPLC-MS to give the peptide with the free chelator (7). We then synthesized
the rhenium tricarbonyl complex, by reacting the peptide with [Re(H2O)3(CO)3]OTf under
microwave conditions. The peptide was then purified by preparative HPLC-MS to give the
peptide Re-7. UV/Vis absorption and fluorescence data are summarized in Table 2.1.
Reported values are very similar to those given by Pope et al. for the four rhenium
naphthalimides they had synthesized, confirming that the fluorophore retains its
fluorescent properties upon conjugation to a peptide, and subjected to aqueous conditions.
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Table 2.1: Photophysical Properties of DPA-Naph Peptide Conjugates.
lmax

e (M-1cm-1)

lem

7

450 nm

14,100

545 nm

0.28

Re-7

439 nm

12,370

527 nm

0.70

Peptide

a

a

b

ff

18 µM in H2O. bRelative to [Ru(bpy)3](PF6)2 in aerated H2O (ff = 0.04)

2.2.2

In Vitro Evaluation of Re-7

To investigate the influence of the DPA-Naph moiety and metal complex on the peptide’s
ability to bind to CXCR4, competitive binding assays were performed using stably
transfected U87.CD4.CXCR4 cells with [125I]-SDF-1 as the competing ligand. Under our
assay conditions, the parent peptide T140 (6) gave an IC50 value of 1.0 nM, while Re-7
only showed a modest increase in IC50 to 1.9 nM (Figure 2.2). This indicates that
conjugation of the DPA-Naph moiety, and formation of the rhenium tricarbonyl complex
has little influence on the ability of the peptide to bind the receptor, as the D-Lys8 side chain
is located outside of the CXCR4 binding pocket.

Figure 2.19: Representative competitive binding curves of T140 (black curve) and Re-7
(grey curve) using U87.CD4.CXCR4 cells with [125I]-SDF-1 as the competing radioligand.
Confocal fluorescence microscopy was then performed to validate Re-7 as a fluorescent
imaging agent specific for CXCR4. U87.CD4.CXCR4 and U87.CD4 cells were incubated
with Re-7 and were then fixed and mounted on slides for imaging. U87.CD4.CXCR4 cells
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showed strong fluorescence, while U87.CD4 cells did not (Figure 2.3), indicating that Re7 can selectively detect CXCR4 in cells expressing the receptor.

Figure 2.20: Confocal microscope images of U87.CD4.CXCR4 cells (A, C) and U87.CD4
cells (B, D) incubated with Re-7. lEx = 458 nm, lEm = 500-550 nm, 40x objective.
It has been previously reported in the literature that PCa cell lines such as PC-3 and DU
145 express CXCR4 to a much higher extent than benign prostate cells such as BPH-1.13
These three cell lines were also incubated with Re-7 and observed by confocal microscopy
to evaluate CXCR4 expression (Figure 2.4). BPH-1 cells showed no discernable
fluorescence. Both PC-3 and DU 145 cells however, displayed observable fluorescence.
The fluorescence intensity was not as strong as that seen in U87.CD4.CXCR4 cells due to
the endogenous expression of CXCR4 being lower in the PCa cells than in the transfected
cells. As CXCR4 expression was observable in the PCa cells and not in the BPH cells, Re7 may be useful in ex vivo analysis of prostate tissue to differentiate benign and malignant
prostate tissue by their CXCR4 expression.
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Figure 2.21: Confocal microscope images of BPH-1 (A, D), PC-3 (B, E) and DU 145 cells
(C, F) incubated with Re-7. lEx = 458 nm, lEm = 500-550 nm, 40x objective.

2.2.3

99m

Tc-labelling and In Vitro Cellular Uptake

Peptide 7 was also radiolabelled with 99mTc to give [99mTc]Tc-7. The peptide was labelled
by reaction with [99mTc]Tc(CO)3(H2O)3+ under microwave conditions. The radiolabelled
peptide was purified by semi-preparative HPLC, giving decay corrected radiochemical
yields ranging from 60-85%, radiochemical purities of >95% (Figure 2.5, left) and molar
activities of 36-44 GBq/µmol.
Cellular uptake of [99mTc]Tc-7 was evaluated in U87.CD4.CXCR4 cells in comparison to
U87.CD4 cells (Figure 2.5, right). Approximately two-fold higher uptake was observed in
the CXCR4 expressing cells (10.4 ± 0.8%) compared to the U87.CD4 cells (5.6 ± 0.1%).
While there was a relatively high amount of non-specific binding observed as seen by the
high uptake in U87.CD4 cells, the radiolabelled peptide shows specific uptake in CXCR4
expressing cells.
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Figure 2.22: (Left) UV-HPLC chromatogram of Re-7 (blue) overlaid with the radio-HPLC
chromatogram of [99mTc]Tc-7 (black). (Right) In vitro cellular uptake of [99mTc]Tc-7 in
U87.CD4.CXCR4 cells in comparison to U87.CD4 cells.

2.2.4

Ex Vivo Biodistribution Studies

Ex vivo biodistribution studies were performed with [99mTc]Tc-7 in NOD/SCID mice
bearing U87.CD4.CXCR4 tumors. The animals were sacrificed at 2 hours post-injection,
and the activity was determined in the organs of interest (Figure 2.6). Uptake in the liver
and kidneys was quite high (22.67 ± 5.02 and 25.69 ± 15.19 % ID/g respectively), which
is consistent with several other radiolabelled T140 derivatives due to hepatic metabolism
and urinary clearance.27,31,32 Moderate uptake was also observed in the lung, spleen,
intestines and stomach. The stomach is known to express CXCR4 to a small degree,33 so
this may account for some of the uptake. However, previous reports also suggest that
hydrophobic imaging labels may increase non-specific uptake in undesired tissues,34
including the stomach.27 Therefore, the uptake may be non-specific, driven by the relatively
non-polar naphthalimide metal complex. The lung, spleen and intestinal uptake is likely
caused by specific binding to CXCR4, as these organs are known to have moderate
expression of the receptor,22 and previously reported CXCR4-targeted radiotracers are
known to specifically accumulate in these organs. Disappointingly, tumor uptake was quite
low (0.51 ± 0.09 % ID/g). This may be due to a combination of higher blood uptake (1.91
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± 0.16 % ID/g) compared to many other T140-based radiotracers along with specific
accumulation in other organs. Optimization of the biodistribution of the peptide is required
to improve the tumor uptake. Several T140 derived peptides have been reported that retain
affinity for CXCR4 such as TN14003 and Ac-TZ14011, so exploration of other derivatives
may help to improve the biodistribution. Alteration of the structure of the metal chelator to
reduce lipophilicity may also lead to a peptide with an improved biodistribution and
pharmacokinetic profile.

Figure 2.23: Ex vivo biodistribution of [99mTc]Tc-7 in U87.CD4.CXCR4 tumor bearing
mice at 2 hours post-injection (n = 3).

2.3 Conclusions
In summary, we have developed a novel T140 derivative (7) containing a 4-amino-1,8naphthalimide appended with a di-(2-picolyl)amine (DPA) binding unit to chelate Re(I)tricarbonyl for use in confocal fluorescence microscopy, and

99m

Tc(I)-tricarbonyl for use

as a SPECT imaging agent. Re-7 showed specific uptake in U87.CD4.CXCR4 cells, as
well as PC-3 and DU 145 PCa cells, while minimal uptake was observed in U87.CD4 and
BPH-1 cells. This fluorescent peptide may be useful in differentiating malignant tissue
from healthy and benign, as malignant tissue tends to express CXCR4 to a much higher
extent. The technetium-99m labelled variant [99mTc]Tc-7 was prepared in high yield, purity
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and molar activity, and was shown to have two-fold higher uptake in CXCR4 expressing
cells. However, in a murine xenograft model, [99mTc]Tc-7 showed very low uptake in
CXCR4 expressing tumors. Alteration of the metal chelation system appended to the
naphthalimide to one with lower lipophilicity may provide a SPECT imaging agent with
improved biodistribution.

2.4 Experimental
2.4.1

General Experimental

All reagents were purchased from commercial sources and used without further
purification. [Re(H2O)3(CO)3]OTf was synthesized according to a published procedure.35
NMR spectra were recorded on a Bruker AvIII HD 400 spectrometer. All chemical shifts
are reported in ppm and referenced to the residual solvent peaks. High resolution mass
spectra for small molecules were recorded on a Waters Xevo QToF mass spectrometer with
an electrospray ion source in positive mode. For peptides, high resolution mass spectra
were recorded on a Bruker micrOTOF II mass spectrometer with an electrospray ion source
in positive mode. Analytical reversed-phase HPLC-MS was performed on a system
consisting of an Agilent Zorbax SB-C18 column (5 µm, 4.6 x 150 mm), Waters 600
controller and Binary Solvent Pump, Waters Inline degasser, Waters Quattro Micro API
mass spectrometer and Waters Mass Lynx software. Mass spectra were collected using an
ESI source in positive ion mode. The gradient solvent system comprised of solvent A
(CH3CN + 0.1 % TFA) and solvent B (H2O + 0.1 % TFA) at a flow rate of 1.5 mL/min
over 10 minutes with a 5-minute wash cycle at 95% solvent A. The UV absorbance was
detected using a Waters 2998 Photodiode array detector. Peptides were purified by
reversed-phase preparative HPLC-MS on the same system with an Agilent Zorbax PrepHT
SB-C18 column (5 µm, 21.2 x 150 mm) at a flow rate of 20 mL/min. After purification,
the collected fractions were frozen at -78 °C, and lyophilized. Analytical radio-HPLC was
performed on a system comprising of an Agilent Zorbax SB-C18 column (5 µm, 4.6 x 150
mm), Waters 600 controller and Binary Solvent Pump, Waters Inline degasser with a
Carroll & Ramsey radiometric detector connected to a waters e-Sat/IN module and Waters
2498 dual absorbance UV-Vis detector. The gradient solvent system comprised of solvent
A (CH3CN + 0.1 % TFA) and solvent B (H2O + 0.1 % TFA) at a flow rate of 1.5 mL/min
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over 10 minutes with a 5-minute wash cycle at 95% solvent A. Semi-preparative radioHPLC was performed on the same system with an Agilent Zorbax SB-C18 column (3.5
µm, 4.6 mm x 150 mm) at a flow rate of 4 mL/min. UV-Vis spectra were recorded on an
Agilent Cary 60 UV-Vis spectrophotometer. Fluorescence spectra were recorded on a
Photon Technologies International, Inc. Quanta Master – 7/2005. Quantum yields were
determined in aerated H2O solutions of the peptides using [Ru(bpy)3](PF6)2 in H2O (f =
0.04) as a standard.36
Ethyl 3-(6-chloro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propanoate (1)
Triethylamine (1.8 mL, 12.9 mmol) and 4-chloro-1,8-naphthalic anhydride (2.00 g, 8.6
mmol) were added to a solution of b-alanine ethyl ester hydrochloride (2.00 g, 12.9 mmol)
in ethanol (80 mL). The resulting orange suspension was heated to reflux for 16 hours,
which became a clear orange solution upon heating. The solution was cooled to room
temperature, resulting in precipitation of the product as bright yellow needles, which were
collected by filtration, washed with cold ethanol and diethyl ether and dried in vacuo.
Yield: 2.17 g, 6.53 mmol, 76%. 1H NMR (CDCl3, 400 MHz) δ 8.65 (d, J = 7.1 Hz, 1H),
8.59 (d, J = 8.5 Hz, 1H), 8.49 (d, J = 7.9 Hz, 1H), 7.83 (m, 2H), 4.48 (t, J = 7.4 Hz, 2H),
4.14 (q, J = 7.1 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H) ppm. 13C NMR
(CDCl3, 100 MHz) δ 171.2, 163.6, 163.3, 139.2, 132.1, 131.2, 130.8, 129.3, 129.1, 127.9,
127.4, 122.9, 121.4, 60.7, 36.3, 32.7, 14.1 ppm. HR-MS (ESI+): m/z calculated for
C17H15NO4Cl+ [M+H]+ 332.0690; found 332.0710.
Ethyl 3-(6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-1,3-dioxo-1Hbenzo[de]isoquinolin-2(3H)-yl)propanoate (2)
To a suspension of 1 (1.5 g, 4.52 mmol) in DMSO (10 mL) was added tert-butyl (2aminoethyl)carbamate (2.17 g, 13.56 mmol), and the resulting suspension heated to 70 °C
under a nitrogen atmosphere for 16 hours. The resulting orange suspension was cooled to
room temperature and the pH adjusted to 6-7 with 0.1 M HCl. The resulting yellow
precipitate was taken up into DCM, washed with water and brine, dried over MgSO4 and
filtered. The orange solution was reduced to a minimum volume, and precipitation was
induced by the addition of hexanes. The product was collected by filtration as an orange-

47

yellow solid. Yield: 1.42 g, 3.12 mmol, 69%. 1H NMR (CDCl3, 400 MHz) δ 8.56 (d, J =
7.5 Hz, 1H), 8.42 (d, J = 8.4 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 7.6 (t, J = 7.5 Hz, 1H), 7.08
(br. s, 1H), 6.55, (d, J = 8.4 Hz, 1H), 5.13, (t, J = 6.1 Hz, 1H) 4.47 (t, J = 7.5 Hz, 2H), 4.14,
(q, J = 7.1 Hz, 2H), 3.64 (m, 2H), 3.44 (m, 2H), 2.74 (t, J = 7.5 Hz, 2H), 1.47 (s, 9H), 1.22
(t, J = 7.1 Hz, 3H) ppm. 13C NMR (CDCl3, 100 MHz) δ 171.6, 164.6, 164.0, 158.6, 150.3,
134.7, 131.2, 129.9, 127.2, 124.7, 122.7, 120.4, 109.7, 103.3, 80.8, 60.6, 46.8, 39.5, 35.9,
32.9, 29.7, 28.4, 14.2 ppm. HR-MS (ESI+): m/z calculated for C24H30N3O6 [M+H]+
456.2135; found 456.2123.
Ethyl 3-(6-((2-aminoethyl)amino)-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)yl)propanoate (3)
Compound 2 (1.38 g) was dissolved in DCM (5 mL), followed by the addition of
trifluoroacetic acid (5 mL), and stirred for 24 hours. The solvent was removed under
reduced pressure. The resulting orange semi-solid was dissolved in water, the pH adjusted
to 9 with 1 M NaOH, and extracted with DCM. The organic layer was washed with water
and brine, dried over MgSO4, filtered and evaporated under reduced pressure to give the
product as a yellow-orange solid. Yield: 0.60 g, 1.69 mmol, 56% 1H NMR (CDCl3, 400
MHz) δ 8.51 (d, J = 7.3 Hz, 1H), 8.39 (d, J = 8.4 Hz, 1H), 8.14 (d, 1H, J = 8.3 Hz, 1H),
7.56 (t, J = 7.9 Hz, 1H), 6.64 (d, J = 8.5 Hz, 1H), 6.22 (m, 1H), 4.46 (t, J = 7.5 Hz, 2H),
4.14 (q, J = 7.1 Hz, 2H), 3.39 (dt, J = 5.1 Hz, 6.2 Hz, 2H), 3.17 (t, J = 6.2 Hz, 2H), 2.74 (t,
J = 7.5 Hz, 2H), 1.46 (br. s, 2H), 1.22 (t, J = 7.1 Hz, 3H) ppm.

13

C NMR (CDCl3, 100

MHz) δ 171.6, 164.5, 163.9, 149.8, 134.6, 131.2, 129.8, 126.4, 124.6, 122.8, 120.4, 109.9,
104.4, 60.6, 44.9, 40.1, 35.9, 32.9, 14.2 ppm. HR-MS (ESI+): m/z calculated for
C19H22N3O4 [M+H]+ 356.1610 found; 356.1669.
Ethyl 3-(6-((2-(bis(pyridin-2-ylmethyl)amino)ethyl)amino)-1,3-dioxo-1Hbenzo[de]isoquinolin-2(3H)-yl)propanoate (DPA-Naph-OEt) (4)
To a solution of 3 (0.55 g, 1.55 mmol) in 1,2-dichloroethane (20 mL) was added 2pyridinecarboxaldehyde (0.295 mL, 3.10 mmol), and the solution stirred for 2 hours under
a nitrogen atmosphere. The solution was cooled to 0 °C on an ice-water bath, and sodium
triacetoxyborohydride (0.75 g, 3.56 mmol) was added. The solution was allowed to warm
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to RT, and then stirred for 48 hours. Water was added, and the product was extracted with
chloroform. The organic layer was washed with water and brine, dried over MgSO4,
filtered and concentrated to a minimum volume. The product was precipitated by the
addition of hexanes and collected by filtration as a bright yellow solid. Yield: 0.65 g, 1.21
mmol, 78%. 1H NMR (CDCl3, 400 MHz) δ 8.84 (d, J = 8.4 Hz, 1H), 8.63 (d, J = 7.3 Hz,
1H), 8.59 (d, J = 4.6 Hz, 2H), 8.42 (d, J = 8.4 Hz, 1H), 7.93 (br. s, 1H), 7.70 (t, J = 7.8 Hz,
1H), 7.58 (td, J = 7.7 Hz, 1.7 Hz, 2H), 7.39 (d, J = 7.8 Hz, 2H), 7.17 (dd, J = 7.8 Hz, 5.9
Hz, 2H), 6.55 (d, J = 8.5 Hz, 1H), 4.5 (t, J = 7.6 Hz, 2H), 4.16, (q, J = 7.1 Hz, 2H), 4.02 (s,
4H), 3.41 (m, 2H), 3.07 (t, J = 5.5 Hz, 2H), 2.77 (t, J = 7.6 Hz, 2H), 1.24 (t, J = 7.1 Hz,
3H) ppm. 13C NMR (CDCl3, 100 MHz) δ 171.6, 164.7, 163.9, 158.8, 150.6, 149.3, 136.7,
134.9, 131.1, 130.1, 127.8, 124.3, 123.3, 122.7, 122.3, 120.8, 108.9, 104, 60.5, 59.7, 51,
41, 35.8, 32.9, 29.7, 14.2 ppm. HR-MS(ESI+): m/z calculated for C31H32N5O4 [M+H]+
538.2454; found 538.2449.
3-(6-((2-(Bis(pyridin-2-ylmethyl)amino)ethyl)amino)-1,3-dioxo-1Hbenzo[de]isoquinolin-2(3H)-yl)propanoic acid (DPA-Naph-OH) (5)
To a solution of 4 (0.60 g, 1.12 mmol) in methanol (10 mL) was added NaOH (0.14 g, 3.40
mmol) in H2O (10 mL). The solution was heated to reflux overnight. Upon cooling to RT,
the solvent was removed under reduced pressure, and water (30 mL) was added. The pH
of the solution was adjusted to 7 with 1 M HCl, and the product extracted with DCM. The
organic layer was washed with water and brine, dried over MgSO4, filtered and evaporated
to give the product as a yellow-orange solid. Yield: 0.48 g, 0.94 mmol, 84%. 1H NMR
(CDCl3, 400 MHz) δ 8.65 (d, J = 8.3 Hz, 1H), 8.59 – 8.56 (m, 2H), 8.53 (d, J = 7.3 Hz,
1H), 8.34 (d, J = 8.4 Hz, 1H), 7.65 – 7.53 (m, 4H), 7.37 (d, J = 7.8 Hz, 2H), 7.19 – 7.13
(m, 2H), 6.47 (d, J = 8.6 Hz, 1H), 4.47 (t, J = 7.2 Hz, 2H), 4.01 (s, 4H), 3.39 (s, 2H), 3.03
(dd, J = 5.6, 5.2 Hz, 2H), 2.78 (dd, J = 7.1 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ 164.8,
164.1, 158.41, 150.6, 149.0, 136.9, 135.0, 131.2, 130.0, 127.8, 124.3, 123.6, 122.5, 122.4,
120.6, 108.6, 104.0, 77.3, 77.0, 76.7, 59.6, 51.2, 40.9, 35.8. HR-MS (ESI+): m/z calculated
for C29H28N5O4 [M+H]+ 510.2144; found 510.2141.
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General Peptide Synthesis
Peptides were synthesized by standard Fmoc solid-phase peptide chemistry on Rink Amide
MBHA resin (0.1 mmol scale, 0.52 mmol/g resin loading) in an automated peptide
synthesizer (Syrowave, Biotage Inc.) with deprotection and coupling steps carried out at
room

temperature in

DMF

using

HCTU as a coupling

agent

and

N,N-

diisopropylethylamine (DIPEA) as a base. The N-terminus was left Fmoc-protected for
subsequent modification of the peptides. Alloc deprotection was achieved by treating the
resin with Pd(PPh3)4 (0.1 equiv.) in the presence of PhSiH3 (20 equiv.) in dry DCM for 45
minutes. Disulfide bridges were formed by reaction with I2 (10 equiv.) in 4:1 DMF/H2O
for 1 hour, followed by washing of the resin with DMF (3 x 4 mL), 2% ascorbic acid in
DMF (3 x 4 mL), then again with DMF (3 x 4 mL). The final Fmoc deprotection was
achieved by treatment of the resin with 20% piperidine in DMF for 5 and 15 minutes. Upon
completion of synthesis, the resin was rinsed with DCM and allowed to dry. Peptides were
cleaved from the resin using 4 mL of 95% trifluoroacetic acid, 2.5% triisopropylsilane, and
2.5% distilled water for 5 h. The cleavage cocktail was collected into a 50-mL falcon tube
where 20 mL of ice cold tert-butylmethylether (TBME) was slowly added to precipitate
the crude peptide. Falcon tubes were centrifuged at 3000 rpm for 10 minutes resulting in a
peptide pellet. The remaining TBME was decanted and peptide pellet was re-suspended in
20 mL of fresh ice-cold TBME before being centrifuged again. The resulting peptide pellet
was dissolved in water, frozen in dry ice and freeze-dried overnight using a lyophilizer.
The crude peptides were analyzed by analytical HPLC-MS.
Synthesis of T140 (6)
The D-Lys side chain was protected with a Boc group. The peptide was cleaved from the
resin following disulfide bridge formation and Fmoc deprotection. Purification was
performed by preparative HPLC-MS (linear gradient 10-70% Solvent A in B) and was
obtained as a fluffy white powder with a purity of 95% after freeze drying of the collected
fractions. HPLC (10-70% Solvent A in B) tR = 9.32 min. HRMS (ESI+): m/z calculated for
C90H143N34O17S2 [M+H]+ 2036.0807; found 2036.0819.
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Synthesis of DPA-Naph-T140 (7)
The D-Lys side chain was protected with an Alloc group. Following Alloc deprotection,
DPA-Naph-OH (3 equiv.) was coupled to the peptide by activation with HCTU (3 equiv.)
in the presence of DIPEA (6 equiv.) in DMF for 2 hours. This was followed by disulfide
bridge formation, Fmoc deprotection and cleavage of the peptide from the resin.
Purification was performed by preparative HPLC-MS (linear gradient 20-80% Solvent A
in B) and was obtained as a fluffy bright-yellow powder with a purity of 96% (by HPLC)
after freeze drying of the collected fractions. HPLC (20-80% Solvent A in B) tR = 8.03
min. HRMS (ESI+): m/z calculated for C119H168N39O20S2 [M+H]+ 2527.2764; found
2527.2671.
Synthesis of Re(CO)3-DPA-Naph-T140 (Re-7)
To a solution of 7 in dH2O (3 mL) in a 5 mL microwave vial was added a 0.1 M solution
of [Re(CO)3(H2O)3]OTf (1.2 equiv.) in H2O. The reaction was heated to 110 °C for 15
minutes under microwave irradiation. The peptide was then purified by preparative HPLCMS (linear gradient 20-80% Solvent A in B) and was obtained as a fluffy, bright-yellow
powder with a purity of >98% (by HPLC) after freeze drying of the collected fractions.
HPLC (20-80% Solvent A in B) tR = 9.63 min. HR-MS(ESI+): m/z calculated for
C122H167N39O23185ReS2 [M]+ 2795.2063; found 2795.2077.
99m

Tc-Labelling of 7

Sodium boranocarbonate (10.0 mg, 0.10 mmol), sodium carbonate (15.0 mg, 0.14 mmol),
sodium borate (20 mg, 0.05 mmol), and sodium potassium tartrate (22 mg, 0.08 mmol)
were dissolved in dH2O (1 mL). This solution was transferred to a sterile vial containing
500-1000 MBq [99mTc]NaTcO4 from a 99Mo/99mTc generator, and then transferred to a 2
mL microwave vial, which was heated in a microwave reactor for 3.5 minutes at 110 °C to
form [99mTc]Tc(CO)3(H2O)3+. The mixture was neutralized by the addition of 1 M HCl (0.2
mL). Approximately 200-500 MBq of [99mTc]Tc(CO)3(H2O)3+ was added to 7 (0.1 mg) in
dH2O (0.1 mL) in a 2 mL microwave vial and heated to 100 °C for 12 minutes in the
microwave reactor. Upon cooling, the reaction mixture was purified by semipreparative
HPLC (linear gradient 20-70% Solvent A in B) to give the labelled peptide in decay
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corrected radiochemical yields ranging from 60-85%, radiochemical purities >95% and
molar activities of 36-44 GBq/µmol.
Cell Culture
U87.CD4 and U87.CD4.CXCR4 cells were obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH from Dr. Hong Kui Deng and Dr. Dan R.
Littman.37 PC-3 and DU 145 cells were purchased from ATCC. BPH-1 cells were a
generous gift from Dr. John Lewis (University of Alberta). U87.CD4.CXCR4 cells were
maintained in DMEM – high glucose (Sigma) containing 15% fetal bovine serum (FBS),
1 µg/mL puromycin, 300 µg/mL G418, and 1X penicillin-streptomycin. U87.CD4 cells
were maintained in DMEM – high glucose (Sigma) containing 10% FBS, 300 µg/mL
G418, and 1X penicillin-streptomycin. PC-3 cells were maintained in F-12K medium
(Wisent) supplemented with 10% FBS and 1X penicillin-streptomycin. DU 145 cells were
maintained in EMEM (Sigma) supplemented with 10% FBS, 1X MEM non-essential
amino acids (Sigma), 2 mM L-glutamine, 1 mM sodium pyruvate and 1X penicillinstreptomycin. BPH-1 cells were maintained in RPMI 1640 medium (Wisent) containing
10% FBS and 1X penicillin-streptomycin. All cell lines were cultured at 37°C in
humidified atmosphere with 5% CO2 and passaged 2 to 3 times per week.
Confocal Microscopy
48 hours prior to the experiment, cells were seeded onto coverslips in 12-well plates
(100,000 cells/well). The culture media was removed, and each well was then washed with
phosphate buffered saline (PBS, 1 mL). Re-7 was dissolved in culture media at a
concentration of 1 µM, and 1 mL of this solution was added to each well. The cells were
incubated at 37 °C for 1 hour. After the incubation, each well was washed with PBS (2 x 1
mL) and fixed by the addition of 4% paraformaldehyde in PBS for 15 minutes. Each well
was then washed with PBS (2 x 1 mL), and the cover slips mounted on slides with
ProLong® Diamond antifade mountant (Molecular Probes). After allowing the slides to
cure for 24 hours, cells were imaged by confocal microscopy on an Olympus Fluoview
FV1000 confocal microscope using a 40x objective. The excitation wavelength was set at
458 nm and emission collected from 500-550 nm.
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Competitive Binding Assays
CXCR4 affinities were determined through competitive binding assays using
U87.CD4.CXCR4 cells with [125I]-SDF-1 as the radioligand. T140 was used as a reference
to ensure the validity of the results. The peptide of interest (at concentrations ranging from
10-12 to 10-6 M) and [125I]-SDF-1 (20 pM) were mixed with the binding buffer (20 mM
HEPES, 0.5% BSA in PBS, pH 7) in 1.5 mL Eppendorf Protein LoBind vials. A suspension
of U87.CD4.CXCR4 cells (50,000 cells) was added to each vial to give a final volume of
300 µL. The vials were shaken at 550 rpm for 20 minutes at 37 °C. Immediately after the
incubation, the vials were centrifuged at 13000 rpm for 5 minutes and the supernatant
removed. The cell pellet was washed with 500 µL of 50 mM Tris buffer (pH 7) and
centrifuged again. The amount of [125I]-SDF-1 bound to the cells was measured using a
gamma counter (Perkin Elmer). IC50 values were determined by non-linear regression
analysis to fit a 4-parameter dose response curve using GraphPad Prism (Version 6.0c).
Cellular Uptake Assay
48 hours prior to the experiment, U87.CD4.CXCR4 and U87.CD4 cells were seeded in 6well plates at a density of 3 x 105 cells per well. On the day of the experiment, the cell
media was aspirated, each well rinsed with Hank’s Balanced Salt Solution (HBSS, 2 x 1
mL)), and an additional 2 mL of HBSS added to each well. 0.5 MBq of [99mTc]Tc-7 in 100
µL of HBSS was added to each well and the cells were incubated at 37 °C for 1 hour. The
supernatant was removed, and each well rinsed with HBSS (1 mL). The combined
supernatant and washes represented the free radioligand. The cells were then scraped in
PBS (1 mL) and transferred to tubes for counting. The wells were then rinsed with PBS (2
x 1 mL) and combined with the cells. The bound and unbound radioactivity was counted
on a Perkin-Elmer Wizard 1470 gamma counter. Cell uptake was expressed as percentage
of cell bound activity over total activity.
Biodistribution Studies
The Western University Animal Use Subcommittee of the Canadian Council on Animal
Care approved the protocols for all mouse handling and treatment procedures described in
this study (protocol 2012-033). Male NOD/SCID mice aged 4-6 weeks were
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subcutaneously injected with U87.CD4.CXCR4 cells (2.5 x 106 cells). After 4-6 weeks,
when the tumors had grown to a size of ~0.8 cm, 1.5-2.5 MBq of [99mTc]Tc-7 was
intravenously administered into the tail vein of isoflurane-anesthetized animals (n = 3). The
animals were sacrificed at two hours post-injection. The tissues and organs of interest were
removed and weighed before being counted for radioactivity in a gamma counter.
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Chapter 3

3

A Study of 99mTc/Re-Tricarbonyl Complexes of 4-Amino1,8-Naphthalimides

3.1 Introduction
Functionalized 1,8-naphthalimides are an incredibly useful class of molecules that have
applications as anticancer drugs1,2 and as fluorescent cellular imaging agents.3,4
Substitution of the naphthyl ring with electron donating substituents creates a
naphthalimide with an excited state resulting from intramolecular charge transfer (ICT).
The resulting fluorophore possesses visible light excitation, solvatochromic properties, and
large Stokes shifts.4 Photophysical properties such as absorption and emission
wavelengths, quantum yields, and fluorescent lifetimes can be modulated by appending
metal complexes to the naphthalimide. Metals such as Gd(III),5 Zn(II),6,7 Au(I),8 and
Re(I)9,10 have been used to this end, and have shown exceptional utility in various cellular
imaging applications. Rhenium complexes are of particular interest, as a fluorescent ligand
that can bind rhenium may also bind technetium-99m for the purpose of single photon
emission computed tomography (SPECT) imaging. Fluorescent rhenium complexes may
aid in the preclinical development of SPECT imaging agents by providing insight into
cellular localization and tissue uptake, as well as having uses in staining of ex vivo tissue
samples.11–14
The fac-Re/99mTc(I)-tricarbonyl core is a convenient and robust system that allows for the
use of a wide variety of tridentate ligands to coordinate the metal, resulting in kinetically
stable complexes.15 The choice of ligand is critical for determining the overall charge of
the metal complex, which can have an impact on hydrophilicity, cellular uptake and
localization, as well as biodistribution in an in vivo setting. Pope et al. have recently
developed a set of 4-amino-1,8-naphthalimide ligands containing a di-(2-picolyl)amine
binding unit to coordinate Re(I)-tricarbonyl and varying napthlalimide substituents.9 This
chelation system imparts an overall positive charge to the Re(I) complex. Coordination of
the ligand to Re(I) caused a hypsochromic shift of the absorption and fluorescence
wavelengths, as well as an increase in the fluorescence quantum yields due to suppression
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of quenching by photo-induced electron transfer (PeT). The complexes also showed
increased cellular uptake over the free ligand in most cases. The effect of changing the
naphthalimide substituent showed tunability of cellular uptake of these naphthalimides. For
the purpose of targeted imaging agents, we wished to observe instead the impact that the
charge of the metal complex has on the photophysical and cellular uptake characteristics.
This information could be used for the development and optimization of bioconjugates
containing Re/99mTc naphthalimide complexes for fluorescence and SPECT imaging.
In this work, we report the synthesis of three naphthalimide ligands that have been
appended with different chelation systems. First, L1 contains a di-(2-picolyl)amine ligand
and is comparable to those developed by Pope et al. to serve as a reference. Two novel
ligands were synthesized: L2, containing a binding unit with one picolyl and one carboxyl
arm which results in a neutral metal complex, and L3, with an iminodiacetate ligand
resulting in a negatively charged metal complex (Figure 3.1). We have compared the
photophysical properties of the ligands and their Re(I) complexes and evaluated the cellular
uptake of the Re(I) complexes by confocal microscopy. Finally, we demonstrate for the
first time, the radiolabelling of the three ligands with technetium-99m to highlight their
utility as components of SPECT imaging agents.

Figure 3.24: Structures of the three naphthalimide ligands coordinated to Re or 99mTc.
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3.2 Results and Discussion
3.2.1

Synthesis and Structural Evaluation

The three naphthalimide ligands (L1-L3) were chosen to afford Re(I) complexes with three
different charge states; positive (Re-L1), neutral (Re-L2) and negative (Re-L3). All three
ligands were derived from the precursor amine 3, which was synthesized in three steps
from commercially available 4-chloro-1,8-naphthalic anhydride (Scheme 3.1). The chlorosubstituted naphthalimide 1 was formed in 84% yield by reaction of the anhydride with
glycine methyl ester hydrochloride in ethanol. The Boc protected amine 2 was made in
quantitative yield by reaction of 1 with tert-butyl (2-aminoethyl)carbamate in DMSO. This
was followed by deprotection of the Boc group with TFA to afford the amine 3 in 41%
yield. L1 was then formed by reaction of 3 with 2-picolylchloride in DMF in 68% yield.
L2 was synthesized in 37% yield via a one-pot asymmetric reductive alkylation of 3 with
2-pyridinecarboxaldehyde

and

glyoxylic

acid

monohydrate

using

sodium

cyanoborohydride. Similarly, L3 was synthesized by reductive alkylation of 3 with
glyoxylic acid monohydrate using sodium cyanoborohydride in 50% yield.
The ligands were fully characterized by NMR and mass spectrometry. The Re(I)tricarbonyl complexes were then formed by reaction of the ligands with fac[Re(CO)3(CH3CN)3]OTf in chloroform at 60 °C. As with the free ligands, the complexes
were characterized by NMR and mass spectrometry. In the 1H NMR spectra of Re-L1, the
ethylene protons from the linker and the methylene protons of the picolyl arms were
deshielded in comparison to that of L1 (Figure 3.2, left). A characteristic pair of signals
were observed due to the diastereotopic splitting of the methylene protons of the picolyl
arms. The coupling constant was 16.4 Hz, corresponding to a geminal coupling. This data
confirms that the di-(2-picolyl)amine is indeed bound to the rhenium atom as previously
reported by Pope et al.
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Scheme 3.2: Synthetic route to the three naphthalimide ligands and their Re(I)-tricarbonyl
complexes.
The 13C NMR of Re-L1 showed two new resonances in comparison to L1 at 197.0 and
196.1 ppm which are characteristic of the equatorial and axial carbonyl ligands
respectively. In the 1H NMR spectrum of Re-L3, the ethylene protons from the linker were
deshielded as with Re-L1, but to a much lesser extent. The diastereotopic methylene
protons on the carboxyl arms also show a geminal coupling of 15.8 Hz. However, one pair
of the protons is slightly deshielded, while the other is slightly shielded in comparison to
L3 (Figure 3.2, right). For Re-L2 the picolyl methylene protons shifted similarly to that of
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Re-L1 and the carboxyl methylene protons shifted similarly to those of Re-L3. Therefore,
the methylene proton shift is characteristic of the chelating arm and not of the overall
complex charge. Both pairs of methylene protons showed geminal couplings, again
confirming the binding mode.

Figure 3.25: 1H NMR spectroscopy chemical shifts of the chelator arm methylene (red)
and linker ethylene (black) protons of L1 (top left) and L3 (top right) and changes upon
rhenium coordination (bottom).

3.2.2

Photophysical Properties

The UV/Vis absorption and fluorescence properties of the ligands were compared to those
of the rhenium complexes (Table 3.1). L1 had a broad absorption band with a maximum
at 439 nm. This band is assigned to an intramolecular charge transfer (ICT) of an N®p*
character. L2 and L3 had a similar broad band, however the maximum for both ligands
was at 436 nm, slightly higher in energy in comparison to L1. Interestingly, the molar
extinction coefficient of L1 was significantly higher than those of L2 and L3. It is known
that the nature of the amino substituent on the naphthalimide ring can impact the
absorbance and energy of the ICT band due to orientation effects.10,16 The absorption band
for Re-L1 experienced a hypsochromic shift and a reduction in the molar extinction
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coefficient in comparison to L1, similar to the analogues previously reported by Pope et
al. The ICT absorption band for Re-L2 and Re-L3 underwent similar hypsochromic shifts,
but an increase in the molar absorption coefficients was observed.
Fluorescence emission maxima varied between the three ligands (Table 3.1). L1 had the
lowest energy emission at 528 nm, while L3 had the highest energy emission at 516 nm.
Rhenium coordination caused a hypsochromic shift of the emission maximum for all three
ligands, however the extent of the shift depended on the charge of the complex. The
positively charged Re-L1 induced the largest shift from 528 nm to 506 nm, while the
negatively charged Re-L3 induced the smallest shift from 516 to 512 nm. The excitation
and emission wavelengths for all three complexes are highly compatible with confocal
fluorescence microscopy. The UV/Vis and fluorescence spectra are shown in Figure 3.3.
The quantum yield of L1 increased upon rhenium coordination due to suppression of PeT
quenching pathways as previously reported for this type of complex. However, metal
coordination had little effect on the quantum yields of L2 and L3. This suggests that either
quenching pathways are not suppressed in Re-L2 and Re-L3, or the quenching pathways
were not present in L2 and L3. The quantum yields for both Re-L2 and Re-L3 were lower
than that of Re-L1, however they are still sufficiently high for use in confocal fluorescence
microscopy.

Figure 3.26: UV/Vis absorption (A-C) and fluorescence excitation/emission spectra (DF) of the ligands (lEx = 440 nm) and their rhenium complexes (lEx = 425 nm) in CH3CN
(20 µM).
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Table 3.2: Photophysical properties of the naphthalimide ligands and their Re(I)tricarbonyl complexes.
Compound
lAbs (nm)a
e (L×mol-1cm-1)a lEx (nm)a
lEm (nm)a
ffb
L1

439

14500

444

528

0.27

L2

436

9950

438

520

0.24

L3

436

8300

438

516

0.13

Re-L1

424

14100

422

506

0.45

Re-L2

425

14750

424

510

0.23

Re-L3

428

15000

424

512

0.13

In CH3CN (20 µM). b In aerated CH3CN relative to [Ru(bpy)3](PF6)2 in aerated CH3CN (ff =
0.018).
a

3.2.3

Confocal Microscopy

The cellular permeability of the three Re(I) complexes was evaluated in OVCAR-8 ovarian
cancer cells by confocal fluorescence microscopy (Figure 3.4, see Appendix B for DIC
images). The cells were incubated with the complexes at a concentration of 20 µM and
were then fixed and mounted on slides for imaging. The ethyl ester variant of Re-L1
previously reported by Pope et al was shown to have good cellular permeability in human
osteoarthritic cells, with cytoplasmic and mitochondrial staining. Re-L1 showed similar
uptake and distribution in the OVCAR-8 cells, with strong signal emanating from the
cytoplasm, and organelles (Figure 3.4, D). Re-L2 showed decreased permeability in
comparison to Re-L1 (Figure 3.4, B). Less cytoplasmic uptake was observed, though there
was still a granular staining pattern, likely due to uptake in mitochondria (Figure 3.4, E).
The positive charge of Re-L1 along with the increased lipophilicity of the picolyl ligands
likely are responsible for the high permeability across the negatively charged phospholipid
membrane in comparison to the neutral complex Re-L2. Due to the negative charge on ReL3, it showed poor cellular permeability (Figure 3.4, C). A weak fluorescent signal was,
however, observed emanating from some structures within the cells (Figure 3.4, F). It has
previously been reported that hydrophobic imaging labels may increase non-specific
uptake in an in vivo setting.17 Therefore, the higher polarity of Re-L2 and Re-L3 suggests
that the technetium-99m labelled variants may be ideal for conjugation to biomolecules for
the purpose of SPECT imaging in order to reduce off-target accumulation of an imaging
agent.
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Figure 3.27: Confocal fluorescence microscope images of OVCAR-8 cells (A-C 40x, DF 100x) incubated with: (A, D) Re-L1; (B, E) Re-L2; and (C, F) Re-L3 at a concentration
of 20 µM (lEx = 458 nm).
While the cellular uptake of Re-L1 was the highest, the high cytoplasmic localization could
obscure fluorescent signals from other cellular structures. For applications where specific
targeting of cellular structures is required, Re-L2 might be a more suitable imaging agent.
In any case, we have demonstrated that changing the polarity and charge of the rhenium
complex drastically alters the cellular permeability and localization. This provides the
opportunity to create bioconjugates of these complexes with the potential to tune the
pharmacokinetic properties, cellular permeability and biodistribution depending on the
charge of the chosen complex.

3.2.4

Radiolabelling with Technetium-99m

The previously reported di-(2-picolyl)amine substituted 4-amino-1,8-naphthalimides had
not been labelled with technetium-99m, only with the non-radioactive analogue rhenium
to exploit the fluorescence properties for fluorescence microscopy applications. To
demonstrate the applicability of these ligands as components of SPECT imaging agents,
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we radiolabelled them with technetium-99m. Under aqueous conditions, the ligands were
reacted with [99mTc][Tc(CO)3(H2O)3]+ to form the fac-99mTc(I)-tricarbonyl complexes.
Initially, we chose a temperature of 100 °C for 15 minutes under microwave irradiation to
radiolabel L1. A single radiolabelled product was observed by analytical HPLC of the
reaction mixture; however, the retention time was significantly shorter than for that of the
rhenium complex. We surmised that the methyl ester was hydrolyzed in the aqueous
environment under the high temperatures. Reduction of the temperature to 70 °C for 15
minutes prevented hydrolysis from occurring, and a single radiolabelled product was
observed that matched the retention time of the corresponding rhenium complex (Figure
3.5). These same conditions were applied to L2 and L3. The labelled products were isolated
by semi-preparative HPLC to remove any unlabelled ligand, resulting in radiochemical
yields of the three complexes ranging from 60-95% and radiochemical purities of greater
than 95%. The ease of labelling and purification of the ligands under mild aqueous
conditions makes them suitable as components of SPECT imaging agents.

Figure 3.28: HPLC chromatograms (System II, 20-80% Solvent A) of the 99mTc-labelled
ligands (blue) and their Re-coordinated standards (pink).
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3.3 Conclusions
In summary, we have reported the synthesis and photophysical properties of two new
naphthalimide ligands and their Re(I)-tricarbonyl complexes, and compared them to an
analogue of a previously reported complex. The photophysical properties of the three
complexes are ideal for confocal fluorescence microscopy. Altering the charge and polarity
of the metal complex drastically altered the cellular permeability of the ligands. Re-L1
showed the highest cellular permeability. The neutral complex, Re-L2, although having
decreased cellular permeability compared to Re-L1, had similar cellular distribution,
except with lower cytoplasmic uptake. The cellular uptake of the negatively charged
complex, Re-L3, was limited due to its high polarity, but this property may be ideal for
technetium-99m labelled SPECT imaging agents to reduce non-specific binding in vivo.
The differing cellular permeability of the three complexes demonstrates their vastly
different polarity, which may be exploited for use in in vivo imaging studies. We have also
demonstrated the

99m

Tc-labelling of the three ligands in high yields and radiochemical

purities, making them suitable as components of SPECT imaging agents. Bioconjugates of
these naphthalimides may have applications as dual modality imaging agents for in vitro
and ex vivo tissue staining by fluorescence, and as in vivo SPECT imaging agents.

3.4 Experimental
3.4.1

General Experimental

All reagents were purchased from commercial sources and used without further
purification. NMR spectra were recorded on a Bruker AvIII HD 400 spectrometer. All
chemical shifts are reported in ppm and referenced to the residual solvent peaks. High
resolution mass spectra were recorded on a Thermo Scientific Double Focusing Sector
mass spectrometer for EI or a Bruker micrOTOF II for ESI in either positive or negative
mode. Analytical reversed-phase HPLC-MS was performed on a system consisting of an
Agilent Zorbax SB-C18 column (5 µm, 4.6 x 150 mm), Waters 600 controller and binary
solvent pump and a Waters Quattro Micro API mass spectrometer (System I). Mass spectra
were collected using an ESI source in positive ion mode. The linear gradient solvent system
comprised of solvent A (CH3CN + 0.1 % TFA) and solvent B (H2O + 0.1 % TFA) at a flow
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rate of 1.5 mL/min over 10 minutes with a 5-minute wash cycle at 95% solvent A. The
UV/Vis absorbance was detected using a Waters 2998 photodiode array detector.
Preparative reversed-phase HPLC-MS was performed on the same system using an Agilent
Zorbax PrepHT SB-C18 column (5 µm, 21.2 x 150 mm) at a flow rate of 20 mL/min. After
purification, the collected fractions were frozen at -78 °C, and lyophilized. Analytical
radio-HPLC was performed on a system comprising of an Agilent Zorbax SB-C18 column
(5 µm, 4.6 x 150 mm), Waters 600 controller and Binary Solvent Pump, a Carroll &
Ramsey radiometric detector connected to a Waters e-Sat/IN module and Waters 2498 dual
absorbance UV/Vis detector (System II). The linear gradient solvent system comprised of
solvent A (CH3CN + 0.1 % TFA) and solvent B (H2O + 0.1 % TFA) at a flow rate of 1.5
mL/min over 10 minutes with a 5-minute wash cycle at 95% solvent A. Semi-preparative
radio-HPLC was performed on the same system with an Agilent Zorbax SB-C18 column
(3.5 µm, 4.6 mm x 150 mm) at a flow rate of 4 mL/min. UV-Vis spectra were recorded on
an Agilent Cary 60 UV-Vis spectrophotometer. Fluorescence spectra were recorded on a
Photon Technologies International, Inc. Quanta Master – 7/2005. Quantum yields were
determined on aerated acetonitrile solutions using [Ru(bpy)3](PF6)2 in acetonitrile (ff =
0.018) as a reference.18 fac-[Re(CO)3(CH3CN)3]OTf was prepared according to the
literature.19
Methyl 2-(6-chloro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)acetate (1)
4-Chloro-1,8-napthalic anhydride (2.00 g, 8.6 mmol), triethylamine (0.85 g, 8.5 mmol) and
glycine methyl ester hydrochloride (1.53 g, 17.2 mmol) were added to ethanol (50 mL) and
heated to reflux for 16 hours. The orange solution was cooled to room temperature,
resulting in the formation of the product as an off-white precipitate that was collected by
filtration, washed with ice cold ethanol and then dried under vacuum (2.2 g, 84%). 1H NMR
(400 MHz; CDCl3) δ 8.64 (dd, J = 7.3, 1.0 Hz, 1H), 8.58 (dd, J = 8.5, 1 Hz, 1H), 8.48 (d,
J = 7.3 Hz, 1H), 7.89 – 7.76 (m, 2H), 4.94 (s, 2H), 3.78 (s, 3H). 13C NMR (CDCl3; 100
MHz) δ 168.5, 163.5, 163.2, 139.7, 132.5, 131.6, 131.2, 129.5, 129.3, 128.0, 127.5, 122.7,
121.2, 52.7, 41.4. HRMS (EI): m/z calculated for C15H10ClNO4 [M]+ 303.0298; found
303.0284.
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Methyl 2-(6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-1,3-dioxo-1Hbenzo[de]isoquinolin-2(3H)-yl)acetate (2)
tert-Butyl (2-aminoethyl)carbamate (3.5 g, 21.7 mmol) and compound 1 (2.2 g, 7.2 mmol)
were dissolved in DMSO (10 mL) and heated to 70 °C for 16 hours. The resulting deep red
solution was cooled to room temperature and the pH neutralized with 0.1 M HCl. The
solution was diluted with dichloromethane and washed with water. After drying with
MgSO4 the dichloromethane layer was reduced to a minimal volume under vacuum.
Hexanes was added, resulting in the precipitation of the product as an orange solid which
was collected by filtration, washed with cold hexanes, and dried under vacuum (3.07 g,
quant.). 1H NMR (400 MHz; CDCl3) δ 8.45 (d, J = 7.3 Hz, 1H), 8.36 (d, J = 8.4 Hz, 1H),
8.24 (d, J = 8.4 Hz, 1H), 7.49 (t, J = 7.3 Hz, 1H), 7.04 (br. s, 1H), 6.51 (d, J = 8.5 Hz, 1H),
4.95 (s, 2H), 3.79 (s, 3H), 3.61 (q, J = 5.6 Hz, 2H), 3.43 (q, J = 4.4 Hz, 2H), 1.48 (s, 9H).
13

C NMR (100 MHz; CDCl3) δ 169.7, 164.6, 163.8, 158.4, 150.8, 135.1, 131.5, 127.7,

124.7, 120.5, 109.1, 103.6, 80.7, 52.6, 46.4, 41.2, 39.6, 29.8, 28.5. HRMS (ESI+): m/z
calculated for NaC22H25N3O6 [M+Na]+ 450.1641; found 450.1644.
Methyl 2-(6-((2-aminoethyl)amino)-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)yl)acetate (3)
Compound 2 (3.0 g, 7.02 mmol) was dissolved in dichloromethane (10 mL) and
trifluoroacetic acid (10 mL) and the solution was stirred for 24 hours at room temperature.
The solvent was removed under vacuum and the resulting TFA salt was dissolved in water
and the pH was neutralized with saturated sodium bicarbonate. The product was extracted
into DCM, the organic layer was collected and dried with Na2SO4. The solvent was then
removed under reduced pressure producing a yellow solid (0.95 g, 41%). 1H NMR (400
MHz; CD3OD) δ 8.50 – 8.38 (m, 2H), 8.29 (d, J = 8.5 Hz, 1H), 7.61 (dd, J = 8.3, 7.5 Hz,
1H), 6.80 (d, J = 8.5 Hz, 1H), 4.86 (s, 2H), 3.78 (s, 3H), 3.75 (t, J = 6.2 Hz, 2H), 3.34 (t, J
= 6.2 Hz, 2H). 13C NMR (100 MHz; CD3OD) δ 170.9, 165.6, 165.1, 151.9, 135.8, 132.5,
131.1, 129.6, 126.0, 123.0, 122.2, 110.4, 105.3, 52.9, 42.0, 41.7, 39.2. HRMS (ESI+): m/z
calculated for C17H18N3O4 [M+H]+ 328.1297; found 328.1284.
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L1
To a solution of compound 3 (50 mg, 0.15 mmol) in DMF (4 mL) was added K2CO3 (84
mg, 0.61 mmol), KI (51 mg, 0.31 mmol) and 2-picolylchloride hydrochloride (50 mg, 0.31
mmol). The orange solution was heated to 50 °C for 48 hours. The solution was partitioned
into water (30 mL) and chloroform (50 mL). The aqueous layer was extracted 3 times with
chloroform, and the combined organics were dried over Na2SO4 and concentrated under
reduced pressure to give the product as a yellow-orange solid (L1) (53 mg, 68%). UV/Vis
(CH3CN): lmax/nm (e /L×mol-1cm-1) = 439 (14 500) 340 (2750) 324 (3450) 282 (19 000)
269 (29 500) 263 (33 000) 256 (32 000). 1H NMR (400 MHz; CDCl3) δ 8.85 (dd, J = 8.4,
1.0 Hz, 1H), 8.63 (dd, J = 7.4, 1.0 Hz, 1H), 8.59 – 8.56 (m, 2H), 8.42 (d, J = 8.5 Hz, 1H),
7.98 (s, 1H), 7.69 (dd, J = 8.4, 7.4 Hz, 1H), 7.56 (td, J = 7.8, 1.8 Hz, 2H), 7.37 (d, J = 7.8
Hz, 2H), 7.15 (ddd, J = 7.5, 4.9, 1.0 Hz, 2H), 6.55 (d, J = 8.5 Hz, 1H), 4.96 (s, 2H), 4.01
(s, 4H), 3.77 (s, 3H), 3.43 – 3.36 (m, 2H), 3.09 – 3.02 (m, 2H).

13

C NMR (100 MHz;

CDCl3) δ 169.3, 164.8, 163.8, 158.9, 151.0, 149.4, 136.8, 135.4, 131.6, 130.5, 128.2, 124.4,
123.4, 122.5, 121.0, 108.6, 104.2, 59.9, 52.5, 51.1, 41.3, 41.1. HRMS (ESI+): m/z
calculated for C29H28N5O4 [M+H]+ 510.2142; found 510.2139.
fac-[Re(CO)3(L1)]OTf (Re-L1)
L1 (53 mg, 104 µmol) and fac-[Re(CO)3(CH3CN)3]OTf (56 mg, 104 µmol) were added to
chloroform (5 mL) and heated to 60 °C for 18 hours. The solution was cooled to room
temperature and diethyl ether was added to induce precipitation of the product as a yellow
solid, which was collected by filtration, washed with diethyl ether and dried under vacuum
giving Re-L1 (72 mg, 74%). UV/Vis (CH3CN): lmax/nm (e /L×mol-1cm-1) = 424 (14 100)
338 (4150) 321 (5700) 276 (25 500) 268 (34 800) 259 (35 500) 253 (34 000). 1H NMR
(400 MHz; acetone-d6) δ 8.99 – 8.96 (m, 2H), 8.67 (d, J = 8.5 Hz, 1H), 8.50 (dd, J = 7.3,
1.0 Hz, 1H), 8.38 (d, J = 8.5 Hz, 1H), 8.05 (td, J = 7.3, 1.6 Hz, 2H), 7.74 – 7.67 (m, 3H),
7.48 (t, J = 6.0 Hz, 2H), 7.43 (t, J = 5.3 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 5.54 (d, J = 16.4
Hz, 2H), 5.28 (d, J = 16.4 Hz, 2H), 4.85 (s, 2H), 4.51 (t, J = 6.6 Hz, 2H), 4.33 – 4.27 (m,
2H), 3.73 (s, 3H). 13C NMR (100 MHz; acetone-d6) δ 197.0, 196.1, 169.7, 164.6, 163.7,
161.9, 152.9, 151.0, 141.5, 135.1, 131.9, 130.8, 129.1, 126.7, 125.8, 124.7, 123.2, 121.9,
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110.4, 105.4, 68.7, 68.6, 52.4, 41.5, 40.6, 40.5. HRMS (ESI+): m/z calculated for
C32H27N5O7185Re [M]+ 778.1440; found 778.1471.
L2
Compound 3 (50 mg, 0.15 mmol) sodium acetate (50 mg, 0.61 mmol), acetic acid (70 µL,
1.22 mmol) and 2-pyridinecarboxaldehyde (16 mg, 0.15 mmol) were dissolved in methanol
(5 mL) and heated to 65 °C for 16 hours. Upon cooling to room temperature, glyoxylic
acid monohydrate (21 mg, 0.23 mmol) and NaBH3CN (21 mg, 0.34 mmol) were added,
and the solution stirred at room temperature for 24 hours. The solvent was removed under
reduced pressure and the crude product was purified by preparative HPLC (System I, 2080%) to give the product as a hygroscopic orange solid (27 mg, 37%). UV/Vis (CH3CN):

lmax/nm (e /L×mol-1cm-1) = 436 (9950) 339 (1930) 322 (2350) 279 (13 000) 268 (22 700)
261 (25 500) 255 (24 500). 1H NMR (400 MHz; CD3OD) δ 8.53 – 8.47 (m, 2H), 8.33 –
8.29 (m, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.05 (td, J = 7.9, 1.6 Hz, 1H), 7.76 (d, J = 7.9 Hz,
1H), 7.67 (dd, J = 8.5, 7.4 Hz, 1H), 7.51 – 7.46 (m, 1H), 6.64 (d, J = 8.6 Hz, 1H), 4.88 (s,
2H), 4.42 (s, 2H), 3.92 (s, 2H), 3.78 (s, 3H), 3.63 (t, J = 6.0 Hz, 2H), 3.34 (t, J = 6.0 Hz,
2H).

13

C NMR (100 MHz; CD3OD) δ 173.7, 170.9, 165.7, 165.1, 155.4, 152.0, 145.0,

144.4, 135.9, 132.6, 131.3, 129.6, 126.6, 126.0, 125.9, 123.1, 122.0, 109.6, 105.3, 58.2,
56.5, 54.1, 52.9, 42.0, 41.4. HRMS (ESI+): m/z calculated for C25H25N4O6 [M+H]+
477.1774; found 477.1776.
fac-Re(CO)3(L2) (Re-L2)
Prepared as for Re-L1 but using L2 (22 mg, 46 µmol) and fac-[Re(CO)3(CH3CN)3]OTf
(25 mg, 46 µmol). Precipitation with diethyl ether gave crude product which was purified
by preparative HPLC (System I, 35-85%) to give the pure product as a yellow solid (10
mg, 29%). UV/Vis (CH3CN): lmax/nm (e /L×mol-1cm-1) = 425 (14 750) 340 (3800) 323
(4950) 277 (23 500) 268 (29 000) 262 (34 500) 255 (34 000). 1H NMR (400 MHz; CD3CN)
δ 8.80 (d, J = 5.6 Hz, 1H), 8.56 – 8.53 (m, 1H), 8.47 – 8.40 (m, 2H), 8.09 – 8.02 (m, 1H),
7.77 – 7.70 (m, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.53 – 7.46 (m, 1H), 6.94 (d, J = 8.5 Hz,
1H), 6.36 (br. s, 1H), 4.83 (d, J = 16 Hz 1H), 4.83 (s, 2H) 4.61 (d, J = 16 Hz, 1H), 4.09 –
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3.98 (m, 2H), 3.95 – 3.85 (m, 3H), 3.72 (s, 3H), 3.58 (d, J = 16.6 Hz, 1H). HRMS (ESI+):
m/z calculated for C28H24N4O9185Re [M+H]+ 745.1073; found 745.1082.
L3
Compound 3 (50 mg, 0.15 mmol), sodium acetate (50 mg, 0.61 mmol), acetic acid (70 µL,
1.22 mmol) glyoxylic acid monohydrate (42 mg, 0.46 mmol) and NaBH3CN (21 mg, 0.34
mmol) were dissolved in methanol (5 mL) and stirred at room temperature for 48 hours.
The solvent was removed under reduced pressure and the crude product purified by
preparative HPLC (System I, 15-70%) to give the product as a yellow solid (34 mg, 50%).
UV/Vis (CH3CN): lmax/nm (e /L×mol-1cm-1) = 436 (8700) 339 (1900) 322 (2300) 279 (11
300) 269 (20 900) 261 (22 500) 255 (21 500). 1H NMR (400 MHz; CD3OD) δ 8.64 (dd, J
= 8.4, 1 Hz, 1H), 8.48 (dd, J = 7.4, 1.0 Hz, 1H), 8.33 (d, J = 8.6 Hz, 1H), 7.62 (dd, J = 8.4,
7.4 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 4.87 (s, 2H), 3.87 (s, 4H), 3.77 (s, 3H), 3.58 (t, J =
5.8 Hz, 2H), 3.37 (t, J = 5.8 Hz, 2H). 13C NMR (100 MHz; CD3OD) δ 173.3, 170.8, 165.9,
165.2, 152.5, 136.2, 132.5, 131.4, 130.0, 125.7, 122.9, 122.0, 109.3, 105.3, 55.8, 53.5, 52.9,
42.0, 41.3. HRMS (ESI-): m/z calculated for C21H20N3O8 [M-H]- 442.1250; found
442.1262.
fac-Na[Re(CO)3(L3)] (Re-L3)
L3 (25 mg, 56 µmol) and fac-[Re(CO)3(CH3CN)3]OTf (31 mg, 56 µmol) and sodium
bicarbonate (10 mg, 113 µmol) were added to chloroform (5 mL) and heated to 60 °C for
18 hours then cooled to room temperature. The solvent was removed, and the residue taken
up in methanol (2 mL) and the residual salts were removed by filtration. The product was
precipitated by the addition of diethyl ether (10 mL) to give the product as a yellow-orange
solid that was collected by filtration (16 mg, 39%). UV/Vis (CH3CN): lmax/nm (e /L×mol1

cm-1) = 428 (15 000) 340 (2500) 324 (3200) 278 (22 500) 269 (31 500) 262 (33 000) 256

(32 000). 1H NMR (400 MHz; CD3OD) δ 8.53 – 8.44 (m, 2H), 8.37 (d, J = 8.6 Hz, 1H),
7.64 (dd, J = 8.4, 7.4 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 4.89 (s, 2H), 3.94 (d, J = 15.8 Hz,
2H), 3.88 – 3.72 (m, 9H).

13

C NMR (100 MHz; CD3OD) δ 198.8, 197.6, 182.7, 171.0,

165.8, 165.1, 152.1, 136.1, 132.5, 131.3, 129.6, 125.9, 123.1, 122.1, 110.0, 105.5, 67.9,
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64.2, 52.9, 42.0, 40.7. HRMS (ESI-): m/z calculated for C24H19N3O11185Re [M]- 710.0549;
found 710.0540.
General procedure for radiolabelling with technetium-99m
A lyophilized powder containing sodium boranocarbonate (10.0 mg, 0.10 mmol), sodium
carbonate (15.0 mg, 0.14 mmol), sodium borate (20 mg, 0.05 mmol), and sodium
potassium tartrate (22 mg, 0.08 mmol) was dissolved in 1 mL of deionized water. This
solution was transferred to a sterile vial containing 1 GBq of [99mTc]NaTcO4 from a
99

Mo/99mTc generator, and then transferred to a 2 mL microwave vial. The reaction mixture

was heated in a microwave reactor (Biotage Inc.) for 3.5 minutes at 110 °C to form
[99mTc][Tc(CO)3(H2O)3]+. The pH of the mixture was neutralized by the addition of 1 M
HCl (0.2 mL). 150-250 MBq of the [99mTc][Tc(CO)3(H2O)3]+ was transferred to a 2 mL
microwave vial containing the ligand in methanol (0.1 mL), and the volume made up to 1
mL with deionized water. The resulting solution was heated in the microwave reactor at 70
°C for 15 minutes. The radiolabelled products were then directly purified by semipreparative HPLC (System II, 20-80%). The identity of the radiolabelled product was
confirmed by comparison of the retention time with the corresponding rhenium coordinated
ligand.
[99mTc]fac-[Tc(CO)3(L1)]+ ([99mTc]Tc-L1)
L1 (0.5 mg) was used for labelling. Radiochemical yields: 74 ± 13%. Radiochemical
purities: 99 ± 1%. HPLC (System II, 20-80 %) tR = 10.0 min.
[99mTc]fac-Tc(CO)3(L2) ([99mTc]Tc-L2)
L2 (0.1-0.2 mg) was used for labelling. Radiochemical yields: 66 ± 10%. Radiochemical
purities: 98 ± 2%. HPLC (System II, 20-80%) tR = 9.3 min.
[99mTc]fac-[Tc(CO)3(L3)]- ([99mTc]Tc-L3)
L3 (0.5 mg) was used for labelling. Radiochemical yields: 90 ± 5%. Radiochemical
purities: 96 ± 4%. HPLC (System II, 20-80%) tR = 7.8 min.
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Cell Culture
OVCAR-8 cells were cultured in RPMI 1640 culture medium (Wisent) supplemented with
10% fetal bovine serum (Wisent) and 1X penicillin-streptomycin (Wisent) in a 37 °C
incubator with a 5% CO2 atmosphere. Cells were passaged 2-3 times per week.
Fluorescence Confocal Microscopy
OVCAR-8 cells were seeded at a density of 100,000 cells per well in 12-well plates
containing glass coverslips and allowed to adhere for 24 hours. The culture medium was
removed, and the wells washed with phosphate buffered saline (PBS). A stock solution of
each rhenium complex in DMSO (80 µL, 1 mM) was diluted to 4 mL in culture medium
giving a 20 µM solution. 1 mL of solution was added to each well (n = 2 per rhenium
complex), and the cells incubated for 30 minutes at 37 °C. The culture medium was
removed, and the cells were washed twice with PBS. The cells were then fixed by the
addition of 1 mL of a 4% paraformaldehyde solution in PBS for 15 minutes. After washing
with PBS, the cells were mounted on glass slides using ProLong® Diamond Antifade
Mountant (Invitrogen) for imaging. Confocal fluorescence microscopy was performed on
an Olympus FluoView FV1000 confocal microscope with a 40x or 100x objective, a 458
nm laser for excitation and the emission filter set to 500-550 nm.
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Chapter 4

4

The Development of 99mTc/Re(I) Tricarbonyl [2+1]
Complexes with Peptides Containing 2,2’-Bipyridine
Residues as b-Turn Mimics

4.1 Introduction
4.1.1 Protein Secondary Structure
β-Sheets are a common secondary structural motif in proteins, accounting for >30% of all
protein structures.1 β-sheets are composed of multiple β-strands linked together by
hydrogen bonds in either a parallel or anti-parallel fashion (Figure 4.1), with the latter being
more common. Often, β-strands are linked by a U-shaped turn region called a β-hairpin,
which reverses the overall direction of the peptide strand, arranging them in an anti-parallel
fashion.

Figure 4.29: Parallel (left) versus anti-parallel (right) β-sheets.
β-hairpins are important in biological recognition events such as protein-protein and
protein-peptide interactions.2,3 Their study for the purpose of molecular imaging is
important, as they could be utilized to target medically relevant biological entities with a
propensity to interact with β-hairpins. One such example is the peptide T140, which binds
to the C-X-C chemokine receptor 4 (CXCR4). T140 was derived from the antimicrobial
self-defense peptides tachyplesin and polyphemusin, which were extracted from the
hemocytes of horseshoe crabs. Structurally, T140 contains a disulfide bridge that stabilizes
the anti-parallel β-sheet structure.4 This structure is essential for the peptide’s interaction
with CXCR4, but the turn region is located outside of the CXCR4 binding pocket.5
Modification of the turn region has been shown to be possible without affecting the binding
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of the peptide to the receptor.6,7 Therefore, the development of peptides containing βhairpin mimicking structures may help create diagnostic and therapeutic agents for diseases
involving the CXCR4 receptor such as HIV and cancer.

4.1.2 Imaging Probe Design: Integrated Versus Pendant
Metal-based molecular imaging probes require a method of connecting a targeting
component, such as a peptide, and signaling component, such as a radiometal. This is
typically done through a metal chelator. Two methodologies are employed when designing
metal-containing peptide-based imaging probes (Figure 4.2).8 The most common approach
is the pendant design in which a radiometal is connected to a peptide through a bifunctional
chelator, which is attached to the peptide either through a modified side-chain, or through
one of the termini of the peptide, typically through an amide linkage. By this method, the
metal complex is placed away from the biologically active site. The pendant approach can
be problematic, as modification of the original peptide may result in decreased affinity for
the biological target of interest, and removal of the metal complex from the targeting entity
in vivo can occur by trans-chelation, or enzymatic cleavage. The latter can be mitigated
through the use of single amino acid chelates (SAAC),9 or through conjugation of the
complex to the peptide through linkages other than amide bonds; however these do not
address the issue of decreased affinity to the target of interest.

Figure 4.30: Pendant (left) versus integrated (right) design.
An integrated approach may be able to remedy these issues. With this approach, the metal
complex is integrated into the peptide backbone, effectively “hiding” the radiometal within
the framework of the peptide, resulting in increased stability and making for a more
compact metal complex. It has been shown that smaller technetium complexes have a
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higher likelihood of maintaining the biological activity of the original ligand.10 An example
of an integrated design is the use of a tridentate 2,6-bis(aminomethyl)pyridine ligand
coordinated to rhenium and integrated into a macrocyclic peptide structure as a
replacement for the turn region.11 Integration of the radiometal into the peptide structure
did not interfere with the already present β-sheet secondary structural elements, effectively
integrating the metal complex into the β-hairpin mimic, with the potential for applications
in radiopharmaceuticals.

4.1.3 2,2’-Bipyridine as a Bidentate Chelator
Examples in the literature have shown that peptides containing 2,2’-bipyridine (bpy) can
form β-hairpin structures upon coordination with a metal. A notable example was by
Schneider and Kelly, in which square planar Cu(II) complexes were used to nucleate βhairpin formation.12 Their peptides contain a 6,6’-bis(acylamino)-2,2’-bipyridine residue,
which exists in a transoid conformation prior to metal coordination (Figure 4.3 – left).
Upon coordination with Cu(II), the bipyridine residue forms a cisoid structure (Figure 4.3
– right). This allows for interstrand hydrogen bonds to form, resulting in a β-hairpin
structure.
The ability of bipyridine based peptides to complex with a metal and form a β-turn structure
introduces the possibility of incorporating a radiometal into the peptide structure. Since βsheets are important in biological recognition,2 a bipyridine based β-turn peptide labelled
with a radiometal could allow for their use in nuclear imaging techniques such as SPECT
or PET for the purpose of imaging cancer and other disease states.

Figure 4.31: Square planar Cu(II) complexes of 2,2’-bipyridine nucleating β-sheet
formation.
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There are many examples in the literature of rhenium complexes with bipyridine.13–16 A
bidentate bipyridine ligand and a monodentate ligand such as pyridine or imidazole can
form a Re(I) tricarbonyl complex. Isostructural complexes can also be formed with
technetium-99m to form a radioactive imaging probe. These can be synthesized efficiently
using a microwave reactor in a one-pot, two-step synthesis (Figure 4.4).

Figure 4.32: Synthesis of isostructural [2+1] complexes of Re and 99mTc. A bidentate
bipyridine ligand and monodentate pyridine ligand fill the 3 coordination sites on the
metal center.
This chapter will focus on the design and synthesis of β-hairpin mimicking peptides
containing a bidentate 2,2’-bipyridine chelator for the purpose of coordinating Re/99mTc
towards the development of SPECT imaging agents. The incorporation of a bipyridine
moiety into a peptide would most easily be accomplished by Fmoc solid-phase peptide
synthesis (SPPS), therefore requiring the design of an unnatural Fmoc-amino acid
containing the desired bipyridine moiety (Figure 4.5). After the amino acid has been
incorporated into the peptide, the structure of the peptide will be evaluated by circular
dichroism (CD) spectroscopy. The peptide will then be coordinated to Re/99mTc for the
purpose of nucleating β-sheet formation, and the structure evaluated by CD spectroscopy.

Figure 4.33: Proposed Fmoc-protected 2,2’-bipyridine amino acid.
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4.2 Results and Discussion
4.2.1 Synthesis of 3,3’-Diamino-2,2’-Bipyridine Amino Acid
To synthesize the bipyridine amino acid, 3,3’-diamino-2,2’-bipyridine was used as a
building block, as the two amino groups could be used for further elaboration. The first
synthetic approach taken for the synthesis of 3,3’-diamino-2,2’-bipyridine was the
Ullmann coupling of compound 1 to make the bipyridine 2, followed by hydrolysis of the
acetyl groups to yield the diamine 3 (Scheme 4.1). In the Ullmann coupling, free amines
greatly decrease the yield of the desired product, due to the formation of byproducts. 3Amino-2-chloropyridine was protected with an acetyl group by dissolving it in neat acetic
anhydride and stirring overnight. The acetylated product 1 was obtained in an 85% yield.
Synthetic procedures published in the literature gave a yield of 77% for the Ullmann
coupling of 1, followed by a 95% yield for the hydrolysis of the acetyl groups.17 However,
yields obtained from this reaction were quite low. A 27% yield of 2 was obtained on one
attempt, while all attempts afterwards only yielded recovered starting material.

Scheme 4.3: Initial synthesis of 3,3'-diamino-2,2'-bipyridine.
The low yields obtained in the coupling reaction can be attributed to the lack of reactivity
of the starting material. Electron donating groups are typically inhibiting in Ullmann
couplings. Electron withdrawing groups (EWG) ortho to the halogen are typically
activating towards the formation of the arylcopper(I) intermediate, accelerating the reaction
rate and allowing for coupling at lower temperatures.18 A nitro group in the 3-position
would be ideal as an EWG in this position, as it may be reduced to the amine after
homocoupling. 3-Nitro-2-chloropyridine was used in the coupling reaction with activated
bronze powder as the copper source. TLC indicated that the starting material was consumed
after only 2 hours at 150 °C. After optimization of the reaction and workup conditions,
yields of 40-48% were obtained. Reduction of the nitro groups was then performed with
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SnCl2·2H2O at reflux in concentrated HCl. The diamine 3 was obtained in 90-95% yield.
Formation of the monosuccinamide 5 was achieved by stirring 3 in DCM with succinic
anhydride in yields ranging from 75-90%. Protection of the amine with an Fmoc group
gave 6 in 68-72% yield. This novel amino acid was then suitable for use in SPPS. Scheme
4.2 highlights the synthesis of compound 6.

Scheme 4.4: Synthesis of 3,3'-diamino-2,2'-bipyridine amino acid (6).

4.2.2 Design of a b-Hairpin Peptide
Designing a peptide that is optimal for β-hairpin formation is important, as secondary
structures may not form if the chosen sequence does not stabilize them. Ideally, with a
peptide containing 2,2’-bipyridine, coordination with a metal such as rhenium or
technetium-99m should nucleate β-hairpin formation or stabilize already present secondary
structure. In 1996, Ramírez-Alvarado et al. reported on the design and structural
characterization of a peptide system optimized to readily undergo β-hairpin formation.19
Using a program called WHATIF20 and the protein structure database included with the
program consisting of 279 proteins with less than 50% homology, they determined that
peptides containing two-residue turns with three-residue strands were most common. They
developed a peptide designated as BH8, which was shown to form a β-sheet structure by
NMR and CD spectroscopy in water, and was stabilized in 30% 2,2,2-trifluoroethanol
(TFE). Residues on the N-terminal end were defined as -B3, -B2 and -B1, while those on
the C-terminal end were defined as +B1, +B2 and +B3.
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We elected to use this scaffold in the design of our bipyridine β-hairpin peptide. The 2,2’bipyridine based amino acid will emulate the two-residue turn region, with the succinamide
group on the C-terminal end, and a β-alanine on the N-terminal end, which will allow the
two strands to align in an anti-parallel fashion. Due to the trans conformation of 2,2’bipyridine ligands, the non-coordinated peptide should not contain any ordered secondary
structure. Metal coordination should induce formation of a β-sheet. The remaining residues
were mainly chosen due to statistical considerations; however, there were other factors that
were considered as well. The -B2 and +B2 positions were chosen to be threonine residues,
as previous work showed that when present together in a non-hydrogen bonded site, they
had the highest intrinsic propensity of all amino acids for formation of β-hairpins.21 It was
found that positively charged residues are commonly found in the +B1 position, so lysine
was chosen for this position. +B3 was chosen to be tyrosine, as aromatic residues were
found to be quite abundant in that position. Isoleucine and valine were found together at
the -B3 and -B1 positions respectively, twice as often as random chance might predict. A
previous study also determined that interactions between tyrosine and isoleucine at the +B3
and -B3 positions respectively, aided in the stabilization of the β-hairpin when in a
hydrogen bonded site.22 In order to prevent lateral oligomerization of the peptide strands,
arginine residues were added to the termini to cause electrostatic repulsion between the
individual peptide strands. However, this could have the potential side effect of causing
intrastrand electrostatic repulsion. In order to counteract this, glycine was added as a spacer
in between the arginine residues and the -B3 and +B3 residues. Since glycine has few
conformational restrictions, it tends to break secondary structure. This should prevent the
arginine and glycine residues from forming a part of the β-hairpin structure, reducing the
repulsion between the two β-strands. The C-terminus of the peptide will also be modified
with an amide in place of the carboxylic acid in order to improve stability. Figure 4.6 shows
the peptide BH8 compared to our newly designed bipyridine β-hairpin peptide (7).
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Figure 4.34: β-Hairpin peptide BH8 (top). 2,2’-Bipyridine β-hairpin peptide 7 (bottom).

4.2.3 Synthesis of a b-Hairpin Peptide
Synthesis of the diamino-bipyridine peptide was performed by both manual and automated
methods. The peptide was built on Rink amide MBHA resin in order to afford an amide
terminus upon cleavage from the resin. The first five amino acids, KTYGR, were coupled
by automated synthesis using the microwave reactor in a Biotage Syrowave peptide
synthesizer. Couplings were all performed at 75 °C through microwave irradiation.
Compound 6 was coupled manually at room temperature. The bipyridine amino acid was
poorly soluble in DMF, so N-methylpyrrolidinone (NMP) was used instead. Once this was
coupled, the remaining amino acids RGITV-(β-Ala) were coupled using the microwave
reactor. Once cleaved from the resin, the crude peptide was analyzed by HPLC-MS. The
desired peptide was observed as determined by mass spectrometry; however, there were
many other species present in the crude product. One of the most prominent side products
was the peptide containing the first five amino acids plus the bipyridine amino acid. It was
determined that the amino group on the bipyridine amino acid was less reactive than that
of a standard amino acid, due to conjugation with the aromatic system. In order to improve
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the coupling efficiency, Fmoc-β-Ala-OH was coupled twice for 45 minutes at 75 °C in the
microwave reactor, using HATU as the coupling reagent. After these coupling cycles,
approximately equal amounts of peptide with and without the β-Ala residue were present.
After a final coupling at 75 °C for 2 hours, only small amounts of peptide without the βAla residue were observed. Complete coupling was observed with a coupling of 2 hours,
followed by a second 1-hour coupling, both at 75 °C with HATU as the coupling agent.
The remainder of the peptide was synthesized using standard protocols. After the peptide
was cleaved from the resin and purified by reversed-phase HPLC, the pure peptide 7 was
isolated in 14% yield.

4.2.4 Structural Evaluation by Circular Dichroism Spectroscopy
Circular dichroism (CD) spectroscopy was used to evaluate the secondary structure of
peptide 7 (Figure 4.7). The UV-CD spectrum was first acquired on peptide 7 in water. A
negative band was observed with a minimum at 194 nm, which is consistent with a random
coil structure as was expected for the peptide. A positive band was also observed at <180
nm. The spectrum was also acquired in 30% TFE, a secondary structure stabilizing solvent,
to determine if it was possible for secondary structure to form. For a peptide/protein
containing a β-sheet, a negative band in the 210-220 nm range and a positive band in the
190-200 nm range are expected, though some variation in these numbers can be expected.23
A shift of the negative band from 194 nm to 203 nm occurred, and a positive band with a
maximum of 186 nm was observed. The bands observed in the CD spectrum of 7 in 30%
TFE suggest the presence of a certain population of peptide folded into a β-sheet structure,
with the rest existing in a random coil conformation. This indicates that the peptide is
capable of forming secondary structure. Unfortunately, the effect of rhenium coordination
on the secondary structure could not be characterized, as the pure complex could not be
obtained in sufficient quantities, as will be discussed in the next section.
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Figure 4.35: Circular dichroism spectra of peptide 7 in water (blue) and 30% TFE
(orange).

4.2.5 Formation of the [2+1] Rhenium Complex and Radiolabelling
with Technetium-99m
Coordination of peptide 7 to rhenium was performed in a one-pot two-step synthesis to
form the [2+1] complex. First, 7 was reacted with one equivalent of [Re(CO)3(H2O)3]OTf
under aqueous conditions at 100 °C for 12 minutes under microwave irradiation to form
Re(CO)3(H2O)(7)+. Some uncoordinated peptide was still observed by HPLC-MS, but
longer reaction times nor additional equivalents of the rhenium precursor resulted in
consumption of the peptide. Two peaks of approximately equal intensity were observed in
the HPLC chromatogram that corresponded to Re(CO)3(H2O)(7)+, resulting from the
formation of a pair of coordination isomers due to the asymmetric nature of the peptide
ligand (Figure 4.8). An excess of 4-dimethylaminopyridine (4-DMAP) was added to
displace the H2O ligand, as 4-DMAP was previously shown to form stable [2+1] rheniumbipyridine complexes.24 This step had to be carefully optimized, as long reaction times at
higher temperatures (100 °C) resulted in 4-DMAP displacing 7 to form Re(CO)3(4DMAP)3+, while low temperatures (40 °C) and shorter reaction times resulted in
incomplete formation of the desired Re(CO)3(4-DMAP)(7)+. Nearly complete conversion
was observed when the reaction was performed at 75 °C for 45 minutes.
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Figure 4.36: Coordination of peptide 7 and 4-DMAP with rhenium to form a [2+1]
chelation system.
Purification of the complex was attempted by solid-phase extraction on a Waters C-18 Seppack. While this was successful in removing remaining 4-DMAP, it was unable to remove
Re(CO)3(4-DMAP)3+ resulting from the reaction of 4-DMAP with unreacted
[Re(CO)3(H2O)3]OTf. Purification was then attempted by preparative HPLC. However,
this was also unsuccessful in removing Re(CO)3(4-DMAP)3+ as well as uncoordinated 4DMAP. It was also noted that upon standing in solution at room temperature, an increase
in the amount of uncoordinated peptide was observed over time due to displacement of the
peptide by the solvent. Previous reports suggest that 3,3’-disubstituted 2,2’-bipyridine
ligands form a twisted geometry upon metal coordination due to steric clash of the 3,3’
substituents, preventing the pyridyl rings from forming a planar geometry.17 This is likely
exacerbated by the long peptide strands in 7, causing instability of the metal complex.
Isolation of the pure peptide metal complex was not possible due to its instability. Attempts
to radiolabel the peptide with technetium-99m gave similar results as for coordination to
rhenium (Figure 4.9). Analysis by radio-UHPLC showed a peak corresponding to the [2+1]
technetium-99m complex with 7 and 4-DMAP as observed by comparison to the retention
time of the rhenium complex. Numerous other peaks were observed as well, including one
corresponding to the [99mTc]Tc(CO)3(4-DMAP)3+ complex.
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Figure 4.37: UHPLC chromatograms of the Re coordinated peptide 7 (top) and 99mTclabelled peptide 7 (bottom).

4.3 Conclusions
A novel Fmoc-protected amino acid containing a 2,2’-bipyridine residue (compound 6)
was synthesized in four steps from 3-nitro-2-chloropyridine. The amino acid was
incorporated into a peptide (peptide 7) by solid-phase peptide synthesis. Analysis by CD
spectroscopy confirmed that the peptide exists in a disordered structure but can fold into a
structure resembling a β-sheet in 30% TFE. Coordination of the peptide to Re/99mTc in a
[2+1] fashion yields unstable complexes that were unable to be purified. While peptides
containing the bipyridine amino acid (6) are not suitable for coordination to Re/99mTc for
the purpose of developing molecular imaging agents, they may be more suitable for
applications such as metal ion sensing where isolation of the formed peptide metal complex
is not necessary. Alternatively, amino acids containing 4,4’-disubstituted bipyridines may
allow for the formation of more stable complexes with Re/99mTc.

4.4 Experimental
General Procedures and Materials: All reagents and solvents were purchased from
commercial sources and used without further purification unless otherwise stated. NMR
spectra were recorded on either an Agilent Mercury VX 400 or Inova 400. All chemical
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shifts are reported in ppm and referenced to the residual solvent peaks. Circular dichroism
spectra were obtained on a Jasco J-810 circular dichroism spectropolarimeter.
Manual Peptide Synthesis: Fully protected resin bound peptides were synthesized by
standard Fmoc solid phase peptide synthesis methods. Fmoc protected Rink amide MBHA
resin (loading 0.34 mmol/g or 0.54 mmol/g) was employed as the solid support. Resin was
swollen by suspension in DCM for 15 minutes. Fmoc deprotection was achieved using
20% piperidine in DMF over two cycles (2 minutes, then 15 minutes). Amino acids were
pre-activated for 5 minutes using 3 equivalents of the Fmoc protected amino acid with 3
equivalents of either HCTU or HATU and 6 equivalents of DIPEA (N,Ndiisopropylethylamine) in DMF. The activated ester was added to the resin and coupling
was performed over 60 minutes. The resin was washed consecutively with DMF then
DCM. Cleavage of the side chain protecting groups and the peptides from the resin was
performed using 95% (v/v) TFA, 2.5% (v/v) TIPS and 2.5% (v/v) H2O over a period of 34 hours. The peptides were precipitated from solution with tert-butylmethyl ether (TBME)
and centrifuged for 5 minutes at 3000 rpm. After decanting of the mother liquor, addition
of TBME was repeated and the peptide centrifuged again. H2O was then added, the solution
frozen at -78 °C and lyophilized.
Automated Peptide Synthesis: Automated peptide synthesis was performed using a
Biotage Syrowave automated microwave peptide synthesizer. Fmoc protected Rink amide
MBHA resin (loading 0.34 mmol/g or 0.54 mmol/g) was employed as the solid support.
Resin was swollen by suspending in DCM for 15 minutes prior to inserting the resin into
the automated synthesizer. Fmoc deprotection was achieved by addition of a 40% solution
of piperidine in DMF over two cycles (30 seconds and 12 minutes). Fmoc protected amino
acids were coupled by addition of 4 equivalents of Fmoc protected amino acid in DMF, 4
equivalents of HCTU in DMF and 8 equivalents of DIPEA in NMP (N-methyl
pyrrolidinone). Couplings were performed over 5 minutes at 75 °C by microwave
irradiation. More difficult couplings were performed using HATU with longer periods of
microwave irradiation. Resin cleavage and purification were performed as per manual
peptide synthesis.
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Purification by Reversed-Phase HPLC-MS: Reactions were analyzed using reversedphase analytical HPLC-MS (Agilent Zorbax SB-C18 Column, 5 µm, 4.6 x 150 mm). The
setup consisted of a Waters 600 controller, Waters prep degasser and Waters Mass Lynx
software. The gradient solvent system comprised of solvent A (H2O+0.1%TFA) and
solvent B (ACN + 0.1%TFA) at a flow rate of 1.5 mL/min over 10 minutes with a 5-minute
wash cycle at 95% solvent B. The UV absorbance was detected using a Waters 2998
photodiode array detector. Peptides were purified using reverse phase preparative HPLC
column (Agilent Zorbax PrepHT SB-C18 Column, 5 µm, 21.2 x 150 mm). The flow rate
for preparative HPLC was 20 mL/min. After purification, the collected fractions were
frozen at -78 °C, lyophilized and analyzed by reversed-phase analytical HPLC-MS.
3-acetylamino-2-chloropyridine (1): Compound 1 was synthesized by a published
method from 3-amino-2-chloropyridine (5 g, 38.9 mmol,) and Ac2O (50 mL).17 The pure
acetylated product was collected as colourless needles (5.6 g, 85%). 1H NMR (400 MHz,
CDCl3): δ = 8.71 (dd, J = 8.2 Hz, J = 1.7 Hz, 1 H), 8.10 (dd, J = 4.7 Hz, 1 H), 7.65 (br. s, 1
H), 7.26 (dd, J = 8.2 Hz, J = 4.7 Hz, 1 H), 2.27 (s, 3 H). 13C NMR (100 MHz, CDCl3) δ =
186.8, 143.8, 139.8, 131.9, 129.3, 123.3, 24.8. MS (ESI+): m/z calculated C7H8ClN2O+
[M+H]+ 171.0; found 171.0.
3,3'-diacetylamino-2,2'-bipyridine (2): Compound 2 was synthesized by a modification
of a published procedure.17 Bronze powder (10 g) was activated by stirring in 100 mL of a
2% solution of I2 in acetone for 15 minutes. After filtration, the solid was then treated with
10 mL conc. HCl in 90 mL of acetone for 15 minutes. After filtration and rinsing with
acetone, the bronze powder was dried under high vacuum and then used immediately.
Compound 1 (4.1 g, 24 mmol) was dissolved in dry DMF (25 mL) under N2 atmosphere.
Activated bronze powder (4.0 g, 63 mmol) was suspended in the solution, and heated to
110 °C for 24 hours. The reaction was quenched by the addition of 20 mL of H2O. The
resulting grey solid was filtered, washed with 20 mL H2O, 40 mL conc. NH4OH and then
an additional 20 mL of H2O. The grey cake was suspended in 100 mL of DCM and stirred
vigorously. After filtration, the solvent was removed, and the pure product was isolated as
an off-white solid (0.91g, 27 %). 1H NMR (400 MHz, CDCl3) δ = 9.08 (d, J = 8.3 Hz, 2
H), 8.32 (d, J = 4.2 Hz, 2 H), 7.36 (dd, J = 8.5 Hz, J = 4.6 Hz, 2 H), 2.23 (s, 6 H). 13C NMR
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(100 MHz, CDCl3) δ = 169.3, 141.9, 140.4, 136.6, 129.9, 124.0, 25.5. MS (ESI+): m/z
calculated C14H15N4O2+ [M+H]+ 271.1; found 271.1.
3,3'-diamino-2,2'-bipyridine (3)
Method A: Compound 3 was synthesized by a published procedure from compound 2 (0.9
g, 3.29 mmol).17 The product was isolated as a bright yellow solid (0.47 g, 77%). 1H NMR
(400 MHz, CDCl3): δ = 7.98 (dd, J = 4 Hz, J = 2.1 Hz, 2 H), 7.04 (m, 4 H), 6.28 (br. s, 4
H).

13

C NMR (100 MHz, CDCl3): δ 143.8, 140.6, 135.8, 124.0, 123.0. MS (ESI+): m/z

calculated C10H11N4+ [M+H]+ 187.1; found 187.1.
Method B: Compound 3 was synthesized from compound 4 (3 g, 12.2 mmol) by a
published procedure.17 The pure product was isolated as a bright yellow solid (2.1 g, 93
%).
3,3'-dinitro-2,2'-bipyridine (4): Compound 4 was synthesized by modification of a
published procedure.17 Activated bronze powder (10 g, 157.4 mmol) was suspended in a
solution of 3-nitro-2-chloropyridine (10 g, 63.3 mmol) in 120 mL of dry DMF under N2.
The mixture was heated to 150 °C for 3.5 hours, at which point no more starting material
was observed as indicated by TLC. The hot reaction mixture was then filtered over Celite.
40 mL of conc. NH4OH and 40 mL H2O was added to the resulting solution which was
then extracted multiple times with EtOAc. The combined organic layers were dried over
Na2SO4 and concentrated under reduced pressure until all of the EtOAc was removed and
only DMF was left. Approximately 100 mL of H2O was added to precipitate the crude
product, which was collected by vacuum filtration. The pure product was obtained as a
golden yellow solid by recrystallization from EtOH (3.23 g, 41%). 1H NMR (400 MHz,
CDCl3): δ = 8.88 (dd, J = 4.8 Hz, J = 1.5 Hz, 2 H), 8.59 (dd, J = 8.4 Hz, J = 1.5 Hz, 2 H),
7.65 (dd, J = 8.4 Hz, J = 4.8 Hz, 2 H). 13C NMR (100 MHz, CDCl3) δ 153.1, 151.4, 143.9,
133.0, 124.2. MS (ESI+): m/z calculated C10H7N4O4+ [M+H]+ 247.0; found 247.0.
4-((3'-amino-[2,2'-bipyridin]-3-yl)amino)-4-oxobutanoic acid (H-Bpy-Suc-OH) (5):
Compound 3 (2 g, 10.75 mmol) was dissolved in DCM (40 mL) and succinic anhydride
was added (1.08 g, 10.75 mmol). After a few moments of stirring at room temperature the
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product began to precipitate. After 45 minutes, the reaction mixture was filtered by vacuum
filtration to yield the pure product as a yellow solid (2.67g, 87%). 1H NMR (400 MHz,
DMSO-d6) δ = 12.16 (br. s, 1 H), 8.85 (dd, J = 8.4 Hz, J = 1.6 Hz, 1 H), 8.28 (dd, J = 4.6
Hz, J = 1.6 Hz, 1 H), 7.91 (dd, J = 4.3 Hz, J = 1.6 Hz, 1 H), 7.29 (dd, J = 8.4 Hz, J = 4.6
Hz, 1 H), 7.26 (dd, J = 8.4 Hz, J = 1.6 Hz, 1 H) 7.15 (dd, J = 8.4 Hz, J = 4.3 Hz, 1 H), 2.58
(m, 4 H). 13C NMR (100 MHz, DMSO-d6) δ = 174.1, 170.9, 146.1, 143.4, 141.2, 136.9,
135.4, 128.1, 125.2, 124.8, 122.7, 32.8, 29.2. MS (ESI+): m/z calculated C14H15N4O3+
[M+H]+ 287.1; found 287.1.
4-((3'-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-[2,2'-bipyridin]-3-yl)amino)-4oxobutanoic acid (Fmoc-Bpy-Suc-OH) (6): Compound 5 (2.5 g, 8.74 mmol) was
dissolved in a solution of NaHCO3 (2.2 g, 26.2 mmol) in H2O (150 mL) and cooled to 0
°C in an ice bath. Fmoc-Cl (3.38 g, 13.1 mmol) was added dropwise as a solution in 1,4dioxane over a period of 1 hour. The solution was warmed to room temperature and stirred
overnight. The pH of the solution was adjusted to 1 with concentrated HCl. The resulting
solid was filtered off and recrystallized from toluene to give the pure product as an offwhite solid (2.39 g, 68%). 1H NMR (400 MHz, DMSO-d6) δ = 12.64 (s, 1 H), 12.23 (s, 1
H), 12.16 (s, 1 H), 8.87 (dd, J = 8.5, 1.6 Hz, 1 H), 8.48 (d, J = 8.6 Hz, 1 H), 8.37 (dd, J =
4.6 Hz, J = 1.6 Hz, 1 H), 8.27 (dd, J = 4.6, J = 1.6 Hz, 1 H), 7.83 (d, J = 7.5 Hz, 2 H), 7.61
(d, J = 7.4 Hz, 2 H), 7.49 (dd, J = 8.5, J = 4.6 Hz, 1 H), 7.44 (dd, J = 8.5, J = 4.6 Hz, 1 H),
7.35 (t, J = 7.4 Hz, 2 H), 7.27 (t, J = 7.4 Hz, 1 H), 4.40 (d, J = 6.9 Hz, 2 H), 4.27 (t, J = 6.8
Hz, 1 H), 2.61 (t, J = 6.6 Hz, 2 H), 2.51 (t, J = 6.9 Hz, 2 H). 13C NMR (100 MHz, DMSOd6) δ = 173.99, 171.08, 153.36, 144.02, 142.03, 141.84, 141.38, 141.21, 136.18, 136.00,
129.97, 128.82, 128.11, 127.52, 125.47, 124.70, 120.60, 120.54, 110.81, 66.77, 46.85,
32.60, 29.16. MS (ESI+): m/z calculated C29H25N4O5+ [M+H]+ 509.2; found 509.1.
H-Arg-Gly-Ile-Thr-Val-(β-Ala)-(Bpy-Suc)-Lys-Thr-Tyr-Gly-Arg-NH2

(7):

The

peptide was synthesized and isolated by standard automated methods. Fmoc-β-Ala-OH
was coupled twice at 75 °C under microwave irradiation for 2 hours and 1 hour,
respectively. Purification was performed by preparative reversed-phase HPLC (17% to
50% ACN/H2O + 0.1% TFA). The peptide was obtained as a white powder (20.4 mg, 14%).
MS (ESI+): m/z calculated for C67H106N23O16+ [M+H]+ 1488.8; found 1488.7.
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Chapter 5

5

Amino-Substituted 2,2’-Bipyridine Ligands as
Fluorescent Indicators for Zn(II) and Applications for
Fluorescence Imaging of Prostate Cells

5.1 Introduction
As a divalent cation, zinc has several biological functions including storage and secretion
of insulin from pancreatic beta cells,1 and the maintenance of prostate health through
various mechanisms such as suppression of overall energy production, controlling
apoptosis, and suppressing tumor progression.2–6 The prostate has been shown to have the
highest Zn(II) concentration of any soft tissue.7 Downregulation of zinc transporters in
cancerous prostate tissue results in greatly reduced levels of Zn(II) in comparison to healthy
prostate tissue.2,3 In contrast, in benign prostatic hyperplasia (BPH) Zn(II) levels are
maintained.8 To this end, Zn(II) has garnered much interest as a potential biomarker of
prostate cancer (PCa) and may be useful in differentiating malignant tissue from healthy
and benign tissue.9,10 Fluorescence has become the foremost method for the detection of
Zn(II) in biological systems, as Zn(II) ions are unresponsive to other analytical techniques
due to its electronic nature. Fluorescence offers the flexibility for use in in vitro biological
assays and cellular imaging by fluorescence microscopy. A 3-hydroxychromone based
fluorescent Zn(II) sensor has recently shown promise for differentiating PCa cells from
normal prostate epithelial cells in vitro.11
Fluorescence of ligands coordinated to Zn(II) may be modulated by a variety of
mechanisms,12 including intramolecular charge transfer (ICT),13,14 photo-induced electron
transfer (PeT)15–17 and excited-state intramolecular proton transfer (ESIPT).11,18
Fluorescent ICT agents have been used extensively as sensors for a wide variety of metal
ions. An ICT fluorophore is an organic ligand containing a conjugated electron donor and
acceptor which undergo charge separation upon photoexcitation.19 Upon binding of Zn(II)
to either the electron donor or acceptor sites, the fluorescence excitation and emission
wavelengths shift, giving a fluorescent signal unique to Zn(II). Substituted 2,2’-bipyridine
ligands have shown great promise as Zn(II) sensors.14,18,20–23 When substituted with
electron donating groups, the imine nitrogen atoms act as electron acceptors. Coordination
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of Zn(II) at the acceptor site causes a bathochromic shift of excitation and emission due to
stabilization of the excited state.
In this work, we have prepared several derivatives of 2,2’-bipyridine with electrondonating amine substituents (Figure 5.1). In order to determine the characteristics that
make for an optimal fluorescent Zn(II) indicator, we have characterized the UV/Vis
absorption and fluorescence properties of the ligands, and changes in these properties upon
coordination to Zn(II). We have also applied this knowledge to Zn(II) sensing in a
biological system by comparing the ability of two of the ligands to differentiate PCa cells
from BPH cells by Zn(II) mediated fluorescence.

Figure 5.38: Amine substituted 2,2’-bipyridine ligands.

5.2 Results and Discussion
5.2.1 Synthesis
Five amine-substituted bipyridine ligands were synthesized for evaluation as fluorescent
Zn(II) sensors (Figure 5.1). The series of five ligands were chosen to compare compounds
with differing excited states, and different strengths of electron donating substituents to
determine the characteristics best suited for Zn(II) sensing in a biological system.
Compounds 1 and 2 were synthesized by previously reported methods.24,25 Scheme 5.1
highlights the syntheses of compounds 4, 6, and 7. Compound 4 was synthesized in 25%
yield by a ligand-free Ni(II) catalyzed coupling reaction26 from compound 3, which was
synthesized by Suzuki-Miyaura coupling of 5-bromo-2-chloropyridine with 4-
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aminophenylboronic acid pinacol ester. Compound 6 was synthesized in two steps from
5,5’-dimethyl-2,2’-bipyridine, which was oxidized with potassium permanganate by a
previously reported protocol to form the diacid 5,27 which then underwent a condensation
reaction with o-phenylenediamine in polyphosphoric acid to form the benzimidazole 6 in
75% yield. Methylation of 6 with methyl iodide gave compound 7 in a moderate 43% yield.

Scheme 5.5: Syntheses of bipyridine derivatives 4, 6 and 7.

5.2.2 UV/Vis Absorption Studies
5.2.2.1 Solvent Polarity Effects
The effects of solvent polarity on the UV/Vis absorption spectra were determined for the
bipyridine ligands to aid in characterizing the excited state. The UV/Vis spectra of 1 in nhexane, n-dodecane and acetonitrile had previously been reported by Glasbeek and Toele.28
They described two strong absorption bands around 370 nm and 265 nm corresponding to
S0®S1 and S0®S2 transitions respectively, with maxima that were insensitive to solvent
polarity. The S0®S1 transition was shown to primarily involve p ® p* HOMO-LUMO
transitions of the bipyridine group. We observed similar results in methanol for compound
1 (Table 5.1) with two absorption bands appearing at 364 nm and 265 nm.
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Table 5.3: UV/Vs absorption characteristics of bipyridine ligands and their Zn(II)
complexes in methanol.

[a]

lAbs [nm]

e [L×mol-1cm-1]

1

364, 265

9000, 15000

2

326, 285

19500, 19000

4

355

28500

6

356

42000

7

334

43000

Zn-1[a]

366, 265

9500, 14000

Zn-2

375, 313

14000, 22500

Zn-4

405

28000

Zn-6

365

30000

Zn-7

345

34500

In the presence of 30 equivalents of ZnSO4.

Compound 2 also showed two absorption bands, one centered around 325 nm and the other
around 290 nm. The UV/Vis absorption spectra were taken in a range of solvents with
different polarities to help determine the excited state characteristics. The absorption
maxima for both bands showed a slight dependence on solvent polarity (Table 5.2), with
polar solvents displaying a lower energy absorption than non-polar solvents (330 and 295
nm in DMSO versus 316 and 284 nm in cyclohexane). This positive solvatochromism is
characteristic of an N ® p* ICT excited state. Figure 5.2 depicts the ICT excited state of
compound 2. The S0®S1 transition is of a higher energy than for compound 1 likely due to
the lack of intramolecular hydrogen bonding in compound 2.
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Figure 5.39: Proposed ICT excited state of compound 2.
Table 5.4: Photophysical properties of compound 2 (20 µM) in various solvents.[a] Only
the lowest energy absorption band is shown for clarity.

e
lAbs
[nm]

lEx
[nm]

lEm
[nm]
SS
[cm-1]

CyH

DX

CHCl3

DCM

EtOH

MeOH

CH3CN

DMF

DMSO

2.02

2.22

4.81

8.93

25.3

33

36.6

38.3

47.2

316

323

320

320

328

326

322

330

331

333

335

336

324

335

337

325

336

339

375

386

396

383

405

406

392

400

405

3363

3944

4509

4755

5159

5043

5259

4762

4807

[a]

Abbreviations: CyH, cyclohexane; DX, 1,4-dioxane; CHCl3, chloroform; DCM,
dichloromethane; EtOH, ethanol; MeOH, methanol; CH3CN, acetonitrile; DMF, N,Ndimethylformamide; DMSO, dimethylsulfoxide; e, solvent dielectric constant; SS, Stoke’s
Shift (𝜐"# − 𝜐"% ).
Compound 4 showed a lower energy absorption band in comparison to compound 2 due to
extended conjugation of the aromatic system. A single broad absorption band was observed
around 360 nm. Compound 4 displayed strongly positive solvatochromism of the
absorption band (Figure 5.3) in comparison to 2, likely due to increased charge separation
in the excited state of the molecule. In cyclohexane, the absorption maximum appears at
342 nm but is significantly red shifted to 375 nm in DMSO (Table 5.3).
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Figure 5.40: UV/Vis absorption spectra of compound 4 in (A) non-polar and (B) polar
solvents.
Table 5.5: Photophysical properties of compound 4 (20 µM) in various solvents.
CyH

DX

CHCl3

DCM EtOH MeOH

CH3CN DMF DMSO

e

2.02

2.22

4.81

8.93

25.3

33

36.6

38.3

47.2

lAbs [nm]

342

354

349

350

359

357

356

370

375

lEx [nm]

342

358

351

351

374

360

369

371

379

lEm [nm]

402

423

436

436

498

514

482

484

493

SS [cm-1] 4364 4292

5554

5554

6658

8323

6353

6293

6101

UV/Vis spectra were not obtainable in the full range of solvents for compound 6 due to
poor solubility, however, synthesis of the N,N’-dimethylated derivative 7 allowed for
studies in the full range (Table 5.4, See Appendix C, Table C1 for compound 6 data). Little
solvatochromism was observed in the absorption spectra for both compounds. This is likely
due to the weaker electron donating ability of the benzimidazole groups in comparison to
the amino and aminophenyl substituents of 2 and 4, resulting in a smaller degree of charge
separation in the excited state. This effect was also observed by Zhu et al. when altering
the electron donating ability of aryl groups on their 5-arylvinyl-5’-methyl-2,2’-bipyridyl
(AVMB) fluorophores.14 Lack of solvatochromism in the absorption spectrum does not
necessarily indicate a lack of ICT.
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Table 5.6: Photophysical properties of compound 7 (20 µM) in various solvents.
CyH

DX

CHCl3 DCM EtOH MeOH CH3CN DMF DMSO

e

2.02

2.22

4.81

8.93

25.3

33

36.6

38.3

47.2

lAbs [nm]

343

343

340

340

336

334

337

343

344

lEx [nm]

349

351

350

348

351

346

333

356

354

lEm [nm]

405

415

417

418

429

438

407

427

431

SS [cm-1] 3962 4394

4591

4812

5180

6071

5460

4671

5047

5.2.2.2 Zinc Titration
The ligands were then titrated with ZnSO4 in methanol to determine the changes in the
UV/Vis absorption spectrum over a range of Zn(II) concentrations. This also aids in
characterizing the excited state of the molecules. If an ICT character is observed, a
bathochromic shift of the absorption spectrum is expected upon Zn(II) coordination.
Ideally, the absorption spectrum of the Zn(II) complex should be in the visible portion of
the electromagnetic spectrum (greater than 400 nm) for use as a Zn(II) indicator in
biological systems and for imaging by confocal microscopy. This is because fluorescence
excitation in the UV region is prone to causing autofluorescence, and can be damaging to
live cells in imaging experiments. As well, many confocal microscopes are only compatible
with excitation wavelengths at 405 nm or greater.
Titration of compound 1 with ZnSO4 in methanol (0.1-30 equivalents) showed very little
change in the absorption spectrum (Figure 5.4A). The molar absorption coefficient of the
lowest energy band showed a slight increase, while that of the highest energy band
decreased slightly. The lowest energy band showed a slight red shift (Table 5.1). Zn(II)
coordination would likely not stabilize the excited state of compound 1 due to the lack of
ICT character, therefore showing little change in the absorption characteristics. The
absorption spectrum of the Zn(II) complex is mostly at wavelengths less than 405 nm, so
this ligand is not ideal for imaging by confocal microscopy
In contrast to compound 1, compound 2 showed a large change in the spectrum upon the
addition of even 0.1 equivalents of ZnSO4 in methanol (Figure 5.4B). Absorption bands
with maxima at 326 nm and 285 nm both showed large bathochromic shifts to 375 nm and
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313 nm respectively. Bathochromic shifts of the absorption spectra upon binding to a
cationic species are indicative of an ICT excited state. However, further addition of Zn(II),
from 0.2 up to 30 equivalents, did not result in further changes to the absorption maxima,
and only a slight increase to the molar extinction coefficients was observed up to the
addition of 5 equivalents of Zn(II). With an absorption spectrum entirely below 405 nm,
compound 2 is also not ideal for Zn(II) sensing in biological systems.
Titration of compound 4 with ZnSO4 in methanol resulted in a bathochromic shift of the
absorption maximum from 355 nm to 405 nm (Figure 5.4C), also indicating an ICT excited
state. More subtle transitions in the absorption spectrum were observed for 4 in comparison
to 2, with the most significant changes occuring upon the addition of 0.1-1 equivalents of
Zn(II), and no further changes occuring after the addition of 5 equivalents. With the Zn(II)
complex of compound 4 having an absorption maximum at 405 nm, it may be suitable for
imaging cellular Zn(II).
Both compounds 6 and 7 showed very subtle changes to the absorption wavelengths upon
titration with ZnSO4 in methanol (Figure 5.4D and 5.4E), in contrast to the sharp changes
observed in compounds 2 and 4. For both compounds, 30 equivalents of Zn(II) were
required before no further changes were observed. The Zn(II) complexes show significant
absorption at 405 nm. While this is not near the absorption maximum for either compound,
it is likely to be sufficient for detecting fluorescence from intracellular Zn(II). As
compound 6 has a stronger absorption at 405 nm upon coordination to Zn(II) in comparison
to compound 7, it may be more suitable for the detection of intracellular Zn(II).
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Figure 5.41: UV/Vis absorption spectra of compound 1 (20 µM) (A) compound 2 (B)
compound 4 (C) compound 6 (D) and compound 7 (E) at a concentration of 20 µM in
methanol upon titration with ZnSO4 (0.1-1 equivalents in intervals of 0.1 equivalents, then
2, 3, 5, 10, 20 and 30 equivalents).

5.2.3 Fluorescence Studies
5.2.3.1 Solvent Polarity Effects
The fluorescence emission spectra of compound 1 in n-hexane, n-dodecane and acetonitrile
were previously reported by Glasbeek and Toele,28 showing two emission bands in the
steady-state emission spectra. A higher energy emission around 425 nm corresponds to the
excited Franck-Condon state, and a lower energy emission around 585 nm results from an
excited state intramolecular double proton transfer (ESIDPT), with subsequent emission
from the tautomeric state. Solutions of compound 1 in methanol were also observed to be
weakly fluorescent. However, only a single emission band was observed at 425 nm. It is
known that ESIPT is less favourable in polar solvents, which could result in weaker or
absent emission from the tautomeric form of the molecule in methanol.
For compound 2, 40 µM of N,N’-diisopropylethylamine (DIPEA) was added to each
solution for the fluorimetry experiments, as in certain solvents (DX, CHCl3, DCM and
MeOH) a second excitation and emission band was observed corresponding to the
protonated form of the molecule due to traces of acid present in these solvents. The addition
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of DIPEA caused these bands to disappear. The addition of acid in methanol caused the
first emission band to disappear, and the second emission band to increase in intensity (See
Appendix D, Figure D14). This evidence supports that the second band is from the
protonated species. Compound 2 displayed solvatofluorochromism, with emission maxima
ranging from 375 nm in cyclohexane to 405 nm in DMSO (Table 5.2) indicative of an ICT
excited state.
Compound 4 displayed a high degree of positive emission solvatofluorochromism (Table
5.3), suggesting a polar emissive excited state. In non-polar solvents, emission maxima
were at 402 nm in cyclohexane and 423 nm in 1,4-dioxane and Stokes shifts were relatively
small. In cyclohexane, the emission band has some vibronic band structure which is
indicative of a locally excited state.19 With a slight increase in solvent polarity, the band
becomes more rounded and unstructured, indicating a shift to a solvent stabilized ICT state.
This is consistent with the observations made by Zhu et al. for an ICT excited state with a
strongly donating amino group. In polar aprotic solvents, Stokes shifts were greater than in
non-polar solvents and emission maxima were shifted to 482-493 nm (Figure 5.5). In polar
protic solvents, methanol and ethanol, Stokes shifts were much greater, and emission
maxima were observed at 514 and 498 nm respectively. Stokes shifts for compound 4 were
also greater than those observed for compound 2, likely due to greater solvent interactions
in polar solvents.

Figure 5.42: Fluorescence emission spectra of compound 4 in a range of solvents.
Compounds 6 and 7 (Table 5.4) also showed positive solvatofluorochromism. Stokes shifts
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were generally smaller in comparison to compound 4, due to the weaker electron donating
nature of the benzimidazole. Compound 6 showed structured vibronic bands in 1,4-dioxane
and chloroform, while compound 7 additionally showed structured bands in cyclohexane
(See Appendix D, Figure D13). Compound 7 displayed greater Stokes shifts than
compound 6 in all cases.
For qualitative comparison of the excited-state dipole moments, the Stokes shifts of
compounds 2, 4 and 7 were plotted against the orientation polarizabilities of the solvents
to afford the Lippert plots (Figure 5.6). While the linearity of the plots is generally poor
due to specific solvent interactions (such as hydrogen bonding, and locally excited versus
charge transfer excited states) causing deviation from the Lippert-Mataga model,19 a
correlation between solvent polarity and Stokes shift is observed. The slope of the Lippert
plot of compound 4 is certainly greater than that of compounds 2 and 7, indicating a higher
degree of polarization in the excited state due to the presence of stronger electron donating
groups.

Figure 5.43: Lippert plots of compound 2 (orange), compound 4 (blue) and compound 7
(green).

5.2.3.2 Zinc Titration and Quantum Yield
A change in either the intensity of the fluorescence emission, or the emission wavelength
upon Zn(II) coordination is essential for being able to differentiate fluorescence from the
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free ligand to that of the Zn(II) complex. A high quantum yield for the Zn(II) complex is
also essential in order to have a detectable fluorescence signal.
In stark contrast to the UV-Vis absorption spectrum, the fluorescence wavelengths of 1
undergo significant change upon the addition of Zn(II). The excitation and emission
maxima both undergo a bathochromic shift, however, the Stokes shift decreases slightly.
The emission intensity was also very sensitive to the number of equivalents of Zn(II), with
very subtle changes occuring upon the addition of up to 30 equivalents of the metal ion
(Figure 5.7A). Glasbeek and Toele28 estimated that quantum yields for compound 1 were
on the order of 10-5 in n-hexane, n-dodecane and acetonitrile.
While we have found a rather low quantum yield for 1 in this study as well, a drastic 70fold increase in the quantum yield was observed upon coordination to Zn(II) in aerated
methanol (Table 5.5). This fluorescence enhancement is likely due to the suppression of
quenching pathways observed in the free ligand by restricting rotation and by removing
the intramolecular hydrogen bonding. While this fluorescence enhancement is certainly
desirable for a Zn(II) indicator, the absorption spectrum is primarily in the UV region.
Further elaboration of this ligand to decrease the excitation energy may result in a Zn(II)
sensor suitable for cell imaging by confocal microscopy.

Figure 5.44: Fluorescence emission spectra of compound 1 (A) compound 2 (B)
compound 4 (C) compound 6 (D) and compound 7 (E) at a concentration of 20 µM in

104

methanol upon titration with ZnSO4 (0.2-1 equivalents in intervals of 0.2 equivalents, then
2, 3, 5, 10, 20 and 30 equivalents).
Table 5.7: Fluorescence properties of the bipyridine ligands and their Zn(II) complexes
in methanol.

[a]

lEx [nm]

lEm [nm]

SS [cm-1]

1

342

425

5710

0.0027

2

337

406

5043

0.058

4

360

514

8323

0.07

6

358

433

4838

0.93

7

346

438

6071

0.92

Zn-1[b]

366

442

4698

0.19

Zn-2

377

422

2829

0.18

Zn-4

406

583

7478

0.0097

Zn-6

371

471

5723

0.71

Zn-7

351

481

7700

0.36

[a]

ff

Aerated methanol, compared to quinine sulfate in 0.05 M H2SO4 (f = 0.52)29 [b]In the

presence of 30 equivalents of ZnSO4.
As with the absorption spectrum for compound 2, the fluorescence emission spectrum
showed a sharp change upon the addition of 0.2 equivalents of Zn(II) in methanol. The
emission band was bathochromically shifted from 406 nm to 422 nm. Further addition of
Zn(II) resulted in an increase in the emission intensity, with no changes observed after the
addition of 5 equivalents (Figure 5.7B). As with the absorption spectrum for the Zn(II)
complex, two excitation maxima were observed at 380 and 320 nm. The quantum yield of
compound 2 was higher than for that of compound 1 (Table 5.5). However, the Zn(II)
complex of compound 2 had a remarkably similar quantum yield to that of the Zn(II)
complex of compound 1, giving only a 3-fold increase. A decrease in the Stokes shift was
also observed for the Zn(II) complex of compound 2. While compound 2 was responsive
to Zn(II) concentration, absorption in the UV range prevents its use in Zn(II) sensing in
biological systems.
The quantum yield for compound 4 was similar to that of compound 2 in aerated methanol
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(Table 5.5). We had hoped that a similar increase in quantum yield would be observed for
compound 4 as well upon Zn(II) coordination, however, the Zn(II) complex of compound
4 showed significantly quenched fluorescence. This finding is in agreement with other
ligands containing strongly electron donating amino groups such as aminophenylsubstituted AVMBs14 and phenanthroline30 ligands upon coordination to Zn(II). A
bathochromic shift of the emission band was observed for the Zn(II) complex as expected,
however the Stokes shift was also seen to decrease. As with the absorption spectrum,
titration with Zn(II) showed no further changes to the emission spectrum after the addition
of 5 equivalents of Zn(II) (Figure 5.7C). While the absorption characteristics of compound
4 are ideal, the very low quantum yield of the Zn(II) complex would make visualizing the
metal ion in biological systems challenging.
The quantum yield for compound 6 had previously been reported as f = 0.93 in aerated
methanol,31 which we have confirmed here (Table 5.5). The quantum yield for compound
7 was almost identical to that of compound 6. However, the quantum yields for both
compounds differ greatly upon coordination to Zn(II), which had not been previously
reported on. Compound 6 only showed a marginal decrease in quantum yield while
compound 7 showed a more drastic decrease. However, both Zn(II) complexes were still
highly fluorescent. The Zn(II) complexes of compounds 6 and 7 showed increased Stokes
shifts over the free ligands, and bathochromic shifts of the excitation and emission maxima.
For both compounds 6 and 7, titration of 30 equivalents of Zn(II) was required before no
further change to the emission spectrum was observed (Figure 5.7D and 5.7E). Since the
Zn(II) complexes of compounds 6 and 7 both had significant absorption at 405 nm, while
the free ligands did not, and the quantum yields of the complexes were high, we elected to
further explore these two ligands for sensing Zn(II) in a biological system by confocal
microscopy.

5.2.4 Effects of Other Metal Ions on the Absorption and Emission
Spectra
In order to detect Zn(II) in a complex biological system, it is essential that the fluorescence
response be specific for Zn(II) over other metal ions. The UV/Vis absorption spectra and
fluorescence emission spectra for compounds 6 and 7 were recorded in the presence of
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Zn(II), Fe(III), Cu(II), Mg(II) and Ca(II). These metal ions represent the most abundant
metals in a cellular environment that are likely to cause interference. For both ligands, the
addition of Ca(II) and Mg(II) had no effect on the absorption maximum, and minimal effect
on the extinction coefficient. The addition of Cu(II) resulted in a larger red shift of the
absorption spectrum than did Zn(II). The addition of Fe(III) had minimal effect on the
position of the absorption maximum, but greatly increased the extinction coefficients. For
both ligands Ca(II) and Mg(II) also had no effect on the fluorescence emission spectrum,
Cu(II) caused complete quenching of fluorescence, and Fe(III) caused a slight
bathochromic shift with significant quenching (Figure 5.8).

Figure 5.45: UV/Vis absorbance and fluorescence emission spectra of compound 6 (A and
D, black) and compound 7 (B and D, black) in the presence of Fe(III) (brown), Cu(II)
(blue), Mg(II) (magenta), Ca(II) (green) and Zn(II) (red).

5.2.5 Confocal Microscopy of Prostate Cell Lines
PC-3 and DU 145 prostate cancer cells have been previously shown to have an impaired
ability to uptake Zn(II).32,33 In contrast BPH-1 cells retain the ability to accumulate high
levels of intracellular Zn(II). All cell lines were incubated with either compound 6 or 7 at
a concentration of 20 µM for 60 minutes. After the incubation period, cells were fixed with
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4% paraformaldehyde and mounted on slides for imaging by confocal microscopy. Weak
fluorescence was observed in BPH-1 cells after incubation with either compound 6 (Figure
5.9) or 7 (Figure 5.10) for 60 minutes when excited with a 405 nm laser, and emission
collected from 475-575 nm. While the free ligands do show some fluorescence emission
in this range, neither one displays any absorbance at 405 nm. Fluorescence emission then
should be exclusively from the Zn(II) complexes. Therefore the observed background
fluorescence is likely due to cellular uptake of Zn(II) present in the culture medium. This
has been observed with similar fluorescent Zn(II) indicators as well.23 BPH-1 cells
incubated with either compound 6 or 7 followed by a 60 minute incubation with Zn(II) at
a concentration of 200 µM showed a large increase in fluorescence intensity. PC-3 and DU
145 cells displayed no fluorescence upon incubation with compound 6 or 7, and no increase
in fluorescence intensity was observed upon the addition of Zn(II). These results are
promising, as bipyridine ligands have the possibility to differentiate benign and malignant
tissue by Zn(II) mediated fluorescence. Compounds 6 and 7 also have the potential to be
used for Zn(II) sensing in ex vivo malignant, benign and healthy prostate tissues.

Figure 5.46: (A) BPH-1, (B) DU 145 and (C) PC-3 cells incubated with compound 6 (20
µM) for 60 minutes. (D) BPH-1, (E) DU 145 and (F) PC-3 cells incubated with compound
6 (20 µM) for 60 minutes, followed by the addition of ZnSO4 (200 µM) for 60 minutes.
lEx = 405 nm, lEm = 475-575 nm.
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Figure 5.47: (A) BPH-1, (B) DU 145 and (C) PC-3 cells incubated with compound 7 (20
µM) for 60 minutes. (D) BPH-1, (E) DU 145 and (F) PC-3 cells incubated with compound
7 (20 µM) for 60 minutes, followed by the addition of ZnSO4 (200 µM) for 60 minutes.
lEx = 405 nm, lEm = 475-575 nm.

5.3 Conclusions
In summary, we have shown that amino substituted bipyridine ligands are suitable for the
detection of Zn(II) by fluorescence. We have investigated the UV/Vis and fluorescence
properties of five bipyridine ligands in a range of solvents, showing that compounds 2, 4,
6, and 7 display characteristics of intramolecular charge transfer, while confirming
previous reports that compound 1 does not. Quantum yields of compounds 1 and 2 were
rather low but increased 70 and 3-fold respectively upon coordination to Zn(II). Compound
4 had a similar quantum yield to compound 2 but showed a drastic decrease upon Zn(II)
coordination. Compounds 6 and 7 had very high quantum yields. While they decreased
slightly upon Zn(II) coordination, the complexes were still highly fluorescent with
bathochromically shifted UV/Vis and fluorescence spectra. The fluorescence response for
compounds 6 and 7 was selective for Zn(II) over other biologically relevant metal ions. We
have shown that these bipyridine ligands also respond to Zn(II) in a biological system,
using prostate cells as a model system. BPH-1 cells, which are known to accumulate
intracellular Zn(II) showed an increase in fluorescence in response to Zn(II) upon
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incubation with either compound 6 or 7 and excitation at 405 nm. PC3 and DU 145 cells
did not show an increase in fluorescence intensity, indicating low uptake of Zn(II). We
have demonstrated the utility of compounds 6 and 7 in detecting Zn(II) in a cellular
environment. Further investigation of these amino substituted bipyridine ligands may allow
for quantitative determination of Zn(II) concentrations in ex vivo tissue samples, which
may be used as a method for differentiating malignant from benign and healthy prostate
tissue. Furthermore, structural modification of the ligands could allow for lower energy
fluorescence excitation in order to reduce the possible effects of autofluorescence.

5.4 Experimental
General Experimental: All reagents and solvents were purchased from commercial
sources and used without further purification unless otherwise noted. All reactions were
performed in oven-dried glassware under nitrogen atmosphere. Analytical thin-layer
chromatography (TLC) was performed using plastic-backed TLC plates coated with silica
gel 60 F254. Flash chromatography was performed using a Biotage Isolera Prime on KP-Sil
cartridges. NMR spectra were recorded on a Bruker AvIII HD 400 spectrometer. All
chemical shifts are reported in ppm and referenced to the solvent peaks. High resolution EI
mass spectra were collected on a Thermo Scientific Double Focusing Sector mass
spectrometer. UV/Vis spectra were recorded on an Agilent Cary 60 UV/Vis
spectrophotometer. Fluorescence spectra were recorded on a Photon Technologies
International, Inc. Quanta Master – 7/2005. Quantum yields were determined on aerated
methanol solutions using quinine sulfate in 0.05 M H2SO4 as a standard (f = 0.52). 3,3’Diamino-2,2’-bipyridine (1),24 5,5’-diamino-2,2’-bipyridine (2),25 and 2,2’-bipyridine5,5’-dicarboxylic acid (5)27 were synthesized according to previously reported procedures.
4-(2-chloropyridin-5-yl)aniline (3): A mixture of 5-bromo-2-chloropyridine (500 mg, 2.6
mmol), 4-aminophenylboronic acid pinacol ester (570 mg, 2.6 mmol), Pd(PPh3)4 (150 mg,
0.13 mmol), and Na2CO3 (550 mg, 5.2 mmol) in 4:1 dioxane/water (25 mL) was heated at
reflux for 24 hours. After cooling to room temperature, the solvent was evaporated, and
the residue taken up in dichloromethane. The organic solution was washed with water and
brine and filtered over an alumina plug. The solvent was evaporated, and the resulting
brown semisolid was purified by automated flash chromatography (Snap 50 g KP-Sil, 10-
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80% EtOAc/Hex) to give the pure product as a beige solid (380 mg, 72%). Rf = 0.38 (40%
EtOAc/Hexanes); 1H NMR (400 MHz, CDCl3) δ = 8.54 (d, J = 2.3 Hz, 1H), 7.76 (dd, J =
8.3, 2.6 Hz, 1H), 7.41 – 7.30 (m, 3H), 6.82 – 6.71 (m, 2H), 3.83 (s, 2H); 13C NMR (100
MHz, CDCl3) δ = 149.1, 147.3, 146.9, 136.3, 135.6, 128.0, 126.4, 124.0, 115.5; HRMS
(EI): m/z calculated for C11H9ClN2+ [M]+ 204.0454; found 204.0451.
5,5'-bis-(4-aminophenyl)-2,2'-bipyridine (4): A mixture of 3 (100 mg, 0.49 mmol),
NiCl2×6H2O (6 mg, 24 µmol), LiCl (21 mg, 0.49 mmol) and Zn dust (38 mg, 0.59 mmol)
in anhydrous DMF (2 mL) was heated to 50 °C. The reaction was initiated by the addition
of a small crystal of I2 and one drop of AcOH, resulting in a colour change from blue to
black. After 2 hours, all starting material had been consumed as indicated by TLC. After
cooling to room temperature, ethyl acetate (10 mL) was added, resulting in the precipitation
of the product as the Zn complex. This was collected by filtration and taken up in 1 M HCl
(3 mL). The solution was then basified by the addition of conc. NH4OH (1 mL), resulting
in the precipitation of the crude product as a brown solid. The product was collected by
filtration, triturated with 1,4-dioxane (5 mL), and once again collected by filtration to give
the pure product as an orange-yellow solid (21 mg, 25%). 1H NMR (400 MHz, DMSO-d6)
δ = 8.89 (d, J = 1.6 Hz, 2H), 8.37 (d, J = 7.6 Hz, 2H), 8.07 (dd, J = 8.3, 2.4 Hz, 2H), 7.55
– 7.47 (m, 4H), 6.73 – 6.63 (m, 4H), 5.40 (s, 4H);

13

C NMR (100 MHz, DMSO-d6) δ =

152.9, 149.7, 146.5, 136.2, 133.6, 127.8, 123.9, 120.5, 114.8; HRMS (EI): m/z calculated
for C22H18N4+ [M]+ 338.1531; found 338.1530.
5,5'-bis(1H-benzimidazol-2-yl)-2,2'-bipyridine (6): To a 250 mL round bottomed flask
containing 5 (500 mg, 2.05 mmol) and o-phenylenediamine (443mg, 4.09 mmol) was
added polyphosphoric acid (~10 mL) and the syrupy suspension was heated to 180 °C in
an oil bath for 24 hours. Upon cooling to 100 °C, deionized water (200 mL) was slowly
added to the dark orange solution, resulting in precipitation of a bright yellow solid. The
flask was removed from the oil bath and stirring continued until all of the viscous
polyphosphoric acid was mixed with the water. Upon cooling to room temperature, the
yellow phosphate salt was collected by filtration and dried under vacuum. The solid was
suspended in deionized water (40 mL), and the pH adjusted to 11 with 6 M potassium
hydroxide. The suspension was stirred at room temperature for 1 hour. The yellow solid
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was collected by filtration, and dried in vacuo (594 mg, 75%). 1H NMR (400 MHz, 1:1
CDCl3:TFA-d) δ = 9.92 – 9.79 (m, 2H), 9.32 – 9.19 (m, 2H), 9.00 – 8.85 (m, 2H), 7.98 –
7.86 (m, 5H), 7.86 – 7.74 (m, 5H);

13

C NMR (100 MHz, 1:1 CDCl3:TFA-d) δ = 148.4,

146.3, 143.3, 143.0, 131.7, 129.8, 125.5, 123.9, 114.8; HRMS (EI): m/z calculated for
C24H16N6+ [M]+ 388.1436; found 388.1435.
5,5'-bis(1-methyl-1H-benzimidazol-2-yl)-2,2'-bipyridine (7): To a solution of 6 (100
mg, 0.26 mmol) in DMF (5 mL) was added Cs2CO3 (78 mg, 0.57 mmol) and methyl iodide
(81 mg, 0.57 mmol) and the resulting bright yellow solution was stirred at room
temperature for 16 hours. The resulting pale-yellow suspension was then diluted with
deionized water (30 mL), and the beige precipitate was collected by filtration and dried in
vacuo (43 mg, 40%). 1H NMR (400 MHz, CDCl3) δ = 9.15 (dd, J = 2.2, 0.7 Hz, 2H), 8.69
(dd, J = 8.2, 0.7 Hz, 2H), 8.33 (dd, J = 8.2, 2.2 Hz, 2H), 7.91 – 7.85 (m, 2H), 7.48 – 7.44
(m, 2H), 7.42 – 7.33 (m, 4H), 3.98 (s, 6H); 13C NMR (10 MHz, CDCl3) δ = 156.2, 150.8,
149.6, 143.3, 138.0, 136.9, 126.9, 123.6, 123.1, 121.4, 120.3, 110.0, 32.0; HRMS (EI): m/z
calculated for C26H19N6+ [M-H]+ 415.1666; found 415.1665.
Cell Culture: PC-3 and DU 145 cells were purchased from ATCC. BPH-1 cells were a
generous gift from Dr. John Lewis (University of Alberta, Edmonton, Alberta). PC-3 cells
were maintained in F-12K medium (Wisent) supplemented with 10% FBS and 1X
penicillin-streptomycin. DU 145 cells were maintained in EMEM (Sigma) supplemented
with 10% FBS, 1X MEM non-essential amino acids (Sigma), 2 mM L-glutamine, 1 mM
sodium pyruvate and 1X penicillin-streptomycin. BPH-1 cells were maintained in RPMI
1640 medium (Wisent) containing 10% FBS and 1X penicillin-streptomycin. All cell lines
were cultured in a 37 °C incubator with a 5% CO2 atmosphere. Cells were passaged 2-3
times per week.
Fluorescence Imaging by Confocal Fluorescence Microscopy: In 12-well plates
containing glass coverslips, PC-3, DU 145 and BPH-1 cells were seeded at a density of
100,000 cells per well and allowed to adhere and grow for 24-48 hours. The culture
medium was removed, and the wells washed with PBS (2 x 1 mL). A stock solution of
bipyridyl ligand (200 µL, 1 mM in DMSO) was diluted in culture media (10 mL) giving a
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20 µM solution, which was filtered through a 0.2 µm syringe filter to remove any
precipitates. This solution (1 mL) was added to each well, and the cells incubated for 60
minutes at 37 °C. The culture media was removed and each well washed with PBS (2 x 1
mL). Two wells were then incubated with a 200 µM solution of ZnSO4×7H2O in culture
media (1 mL) for 60 minutes at 37 °C. The culture media was removed, and the cells
washed twice with PBS. The cells were then fixed by the addition of 1 mL of a 4%
paraformaldehyde solution in PBS (1 mL) for 15 minutes. After washing with PBS (2 x 1
mL), the cells were mounted on glass slides using ProLong® Diamond Antifade Mountant
(Invitrogen) for imaging. Confocal fluorescence microscopy was performed on an
Olympus FluoView FV1000 Confocal Microscope using a 40x objective with a 405 nm
laser for excitation and the emission range set to 475-575 nm.
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Chapter 6

6

Conclusions

The field of molecular imaging has provided clinicians and scientists a deeper
understanding of disease, and the underlying cellular and molecular processes. A large tool
palette of molecular imaging agents is available, ranging from PET, SPECT and MRI
imaging probes for in vivo diagnostic imaging, and fluorescent OI imaging probes for
preclinical research applications in cells and tissues. However, there are still unmet needs
in both clinical and research settings for molecular imaging probes that must be
addressed.1–3 Therefore, novel methodologies and approaches to the design of molecular
imaging probes must be taken in order to develop agents that improve upon those that exist
or allow for imaging of new biological targets.
Molecular imaging agents that target GPCRs have become an approach to personalized
medicine in a clinical setting. Determining expression of these receptors in disease allows
for targeted therapeutic approaches, as well as more accurate and sensitive imaging of
disease distribution in the body.4 The GPCR CXCR4 has garnered much attention as a
target for molecular imaging probes in cancer. In chapter 2, the development of a novel
dual modality molecular imaging probe targeting CXCR4 was explored. Dual modality
imaging agents allow for a single entity to be used in different imaging applications, or for
two modalities to be used simultaneously to overcome the disadvantages of each
modality.5,6 It had previously been reported that 4-amino-1,8-naphthalimides containing a
di-(2-picolyl)amine chelator coordinated to rhenium are suitable as fluorescent cellular
imaging agents.7 Replacement of rhenium with technetium-99m opens the doors for the
development of SPECT imaging agents. Though many fluorescent rhenium complexes
have been reported that may also be coordinated to technetium-99m for SPECT imaging,
these agents often suffer from low quantum yields, and the energy required for excitation
is in the UV range.8 This is not ideal for imaging of live cells and tissues, so new agents
with visible light excitation would help to improve the utility of fluorescent rhenium
complexes for imaging applications.
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A 4-amino-1,8-naphthalimide containing a carboxylic acid functionality was synthesized
and conjugated to the D-Lys side chain of the CXCR4 antagonist peptide T140. The peptide
was coordinated to rhenium for in vitro characterization. The rhenium coordinated peptide
retained high fluorescence quantum yields. Through competition binding assays, it was
determined that the rhenium coordinated peptide retained high affinity for CXCR4. By
confocal fluorescence microscopy, it was shown that the peptide was taken up selectively
by cells expressing CXCR4. This provides a possible route to differentiate malignant
prostate cells from healthy and benign, as only malignant cells express CXCR4.
Radiolabelling with technetium-99m was achieved in high radiochemical yield, purity and
molar activity. To my knowledge, this is the first report of a 99mTc(CO)3-labelled CXCR4
imaging agent, and the first 99mTc-labelled T140 derivative. Other technetium-99m labelled
imaging agents targeting CXCR4 use the 99mTc-HYNIC9 or 99mTcO2+ scaffolds,10,11 which
tend to exhibit lower in vivo stability than the

99m

Tc(CO)3 system. These types of

complexes also do not produce rhenium complexes that exhibit luminescence properties.
Peptides such as T140 also provide the opportunity for optimizing structures to improve
biodistribution and pharmacokinetics. Cellular uptake of the radiotracer in CXCR4
expressing cells was two-fold of that in cells that do not express the receptor.
Disappointingly, in NOD/SCID mice bearing CXCR4 expressing tumors, uptake of the
technetium-99m labelled tracer was rather low. A possible reason for the low uptake is the
lipophilic nature of the naphthalimide entity, as this has been shown to cause non-specific
binding in other organs. Even though the metal complex bears a positive charge, the nonpolar nature of the aromatic pyridyl ligands appears to overpower the effects of the charge.
There are several possibilities on how to improve the pharmacokinetic profile of the
radiotracer. Previously reported CXCR4 targeting PET imaging probes that had low tumor
uptake saw a reduction in non-specific binding upon lowering the molar activity of the
radiotracer.12,13 Another feasible approach is to reduce the lipophilicity of the
naphthalimide by altering the metal chelation system. This may help to reduce non-specific
binding in vivo. This newly developed dual modality imaging agent shows promise as a
tool for evaluating CXCR4 expression in cells and tissues by fluorescence imaging,
however improvements are required before it may be used as a SPECT imaging agent.
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As seen in chapter 2, peptides containing technetium-99m labelled 4-amino-1,8naphthalimides may suffer from poor pharmacokinetics in vivo due to their lipophilic
nature. Therefore, the development of less lipophilic naphthalimide-metal complexes is
required in order to address this issue. In order to be useful as dual modality imaging agents,
the fluorescence properties must be suitable for fluorescence imaging. In chapter 3, the
synthesis and evaluation of Re/99mTc coordinated naphthalimides containing three different
chelation systems was discussed. The three ligands were coordinated to rhenium to
evaluate the fluorescence and cellular uptake properties. The fluorescence properties of the
rhenium complexes were all suitable for use in confocal fluorescence microscopy. Upon
incubation with OVCAR-8 cells, it was demonstrated that the cellular uptake of all three
complexes was drastically different. The ligands containing carboxylate chelating arms
showed much lower uptake into the cells, indicating a more polar metal complex. The three
ligands were also radiolabelled with technetium-99m giving high radiochemical yields and
purities. This demonstrates the three ligands’ utility as components of SPECT imaging
agents. This may allow for the tuning of the pharmacokinetic profiles of bioconjugates for
SPECT imaging, while still retaining utility as fluorescence imaging agents.
Cellular localization and uptake of luminescent metal complexes not only has implications
for imaging, but for therapeutics as well. Fluorescence imaging of the cellular localization
of metal complexes may allow for the determination of the mechanism of action of a
potential therapeutic agent. Luminescent ruthenium-polypyridyl complexes bearing
positive charges showed higher uptake in cancer cells than those bearing negative charges,
and both complex types had very different cellular localization.14 While the positively
charged complex displayed significant cytotoxicity in both dark and light conditions due
to the mitochondrial localization, the negatively charged complex only displayed toxicity
upon illumination. This provides the opportunity to develop the complex as an agent for
photodynamic therapy. Visualization of the change in cellular localization upon modifying
the complex charge allowed for the determination of the mechanism of action of this
potential therapeutic agent. Therefore, luminescent metal complexes are a powerful tool
for studying disease.
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While pendant labelling approaches to molecular imaging probes such as that demonstrated
in chapter 2 may not affect a peptides ability to bind to a receptor, in many cases pendant
labels can be detrimental to binding affinity. Integrated labelling approaches may be
beneficial for maintaining high affinity for receptors. However, as demonstrated in chapter
4, the design and implementation of integrated molecular imaging probes presents many
challenges. An Fmoc-protected amino acid containing a 3,3’-diamino-2,2’-bipyridine
residue was successfully synthesized and was incorporated into a peptide through SPPS.
CD spectroscopy showed that the peptide exists in a random coil conformation in an
aqueous environment. Addition of the secondary structure stabilizing solvent TFE resulted
in a secondary structure that more closely resembles a b-sheet. However, coordination of
the bipyridine peptide to rhenium and technetium-99m resulted in unstable metal
complexes that could not be successfully purified or isolated. As previous reports have
shown that bipyridine containing peptides can form b-sheet structures upon metal
coordination,15 and bipyridine complexes of rhenium and technetium-99m are well
known,16,17 it is feasible that they may be used in the development of SPECT imaging
agents containing technetium-99m. The instability of the reported metal complexes results
from steric clash of the 3,3’-substituents on the bipyridine rings, therefore, the use of either
6,6’- or 4,4’-disubstituted bipyridines may be more suitable for this use case. Other
methods for incorporating Re/99mTc into turn mimics have been reported,18 so there is
certainly promise for the field.
Chapter 5 discussed the development of amino-substituted 2,2’-bipyridine ligands as
fluorescent indicators for Zn(II) in a cellular environment. 3,3’-Diamino- and 5,5’diamino-2,2’-bipyridine ligands showed a strong fluorescent response to Zn(II), displaying
a large increase in quantum yield in the presence of the metal ion. However, the excitation
wavelengths required for fluorescence were in the UV region of the electromagnetic
spectrum, which is not ideal for use in fluorescence imaging of live cells. The addition of
aminophenyl substituents resulted in a ligand with ideal excitation wavelengths for live
cell imaging upon coordination to Zn(II), however, the complex was only weakly
fluorescent. Two benzimidazole substituted 2,2’-bipyridine ligands however, gave good
quantum yields upon coordination with Zn(II) and were excitable with visible light for
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cellular imaging. The fluorescence response of the ligands was selective for Zn(II) over
other metal ions. The two bipyridine ligands were employed for cellular imaging of Zn(II)
concentrations in prostate cell lines. A fluorescence response was observed in BPH-1 cells
but not PC-3 and DU 145 PCa cell lines, due to the impaired Zn(II) uptake of the PCa cells.
This allows for the differentiation of benign and malignant prostate tissues, which may
have applications in imaging of ex vivo tissue samples.
Though the field of fluorescent Zn(II) indicators is certainly a crowded one, the need for
new indicators still exists.3 A fluorescent 3-hydroxychromone Zn(II) sensor was previously
shown to be able to differentiate between regular prostate epithelial cells and prostate
cancer cells using two-photon excitation fluorescence microscopy.19 We have
demonstrated that the same can be done with benign prostate cells using confocal
fluorescence microscopy with visible light excitation. Previously reported 2,2’-bipyridine
Zn(II) sensors have been used to detect intracellular Zn(II), but unfortunately could only
be excited with UV light,20 or suffer from poor photostability.21 The 2,2’-bipyridine Zn(II)
sensors reported in this thesis are excitable with visible light upon coordination to Zn(II),
and are therefore more applicable for imaging of live cells. Fluorophores that are able to
be used ratiometrically, and that are useful over a wide range of concentrations, as well as
having defined cellular localization may improve the use of these sensors in the study and
diagnosis of disease. Two-photon excitation microscopy has recently been employed for
ratiometric sensing of intracellular Zn(II) with the sensor Chromis-1.22 Attachment of
organelle targeting tags to Zn(II) sensitive probes has also been demonstrated to allow for
the detection of Zn(II) in specific organelles such as mitochondria.23
In summary, this thesis has highlighted the development of several novel approaches to
molecular imaging agents. Novel methodologies and approaches to incorporating imaging
moieties into molecular imaging agents can lead to the development of new classes of
probes that target cellular and molecular entities that were not previously accessible. The
development of new ways to diagnosis and treat disease may be uncovered through
molecular imaging. Fluorescent naphthalimides containing a variety of metal chelators
may allow for the development of new fluorescent imaging agents that could also be used
for nuclear imaging applications. Alteration of the metal complex allows for the tuning of
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the pharmacokinetic properties of the radiolabelled agent, while still retaining suitable
fluorescence properties. The design of integrated radiopharmaceuticals presents many
challenges, and while incorporation of metal chelators into the backbone of peptides is
certainly possible, the coordination chemistry of the ligand must be carefully tuned in order
to provide stable metal complexes that may be used for in vivo imaging applications.
Though a metal chelator may not be suitable for one application, often other applications
for the molecule may be explored. For example, the 3,3’-diamino-2,2’-bipyridine ligands
developed in chapter 4 were not suitable for coordination to Re/99mTc. However, the
discovery of their fluorescence properties upon coordination to Zn(II) paved the path for
the development of the bipyridine ligands reported in chapter 5. These bipyridine ligands
showed strong fluorescent responses to the presence of Zn(II), and are promising agents
for diagnosing malignancies of the prostate.
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Appendix A: Additional Data for Chapter 2

Figure A48: 1H NMR spectrum (400 MHz; CDCl3) of compound 5 (DPA-Naph-OH).
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Figure A49: 13C NMR spectrum (100 MHz; CDCl3) of compound 5 (DPA-Naph-OH).
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Figure A50: HPLC chromatogram (10-70% CH3CN/H2O + 0.1% TFA) of peptide 6
(T140).
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Figure A51: HPLC chromatogram (20-80% CH3CN/H2O + 0.1% TFA) of peptide 7
(DPA-Naph-T140).
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Figure A52: HPLC chromatogram (20-80% CH3CN/H2O + 0.1% TFA) of peptide Re-7
(Re(CO)3-DPA-Naph-T140).
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Table A8: Ex vivo biodistribution data for [99mTc]Tc-7 in NOD/SCID mice two hours
post-injection (n = 3).
Tissue

Uptake (% ID/g ± SD)

blood

1.91 ± 0.16

heart

0.93 ± 0.04

lung

2.80 ± 0.63

liver

22.67 ± 5.02

spleen

2.05 ± 1.37

pancreas

1.15 ± 0.54

stomach

4.67 ± 0.99

intestine

2.36 ± 1.40

kidney

25.69 ± 15.19

tumor

0.51 ± 0.09

muscle

0.26 ± 0.07

brain

0.10 ± 0.02
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Appendix B: Additional Data for Chapter 3

Figure B53: 1H NMR spectrum (400 MHz; CD3OD) of compound 3.
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Figure B54: 13C NMR spectrum (100 MHz; CD3OD) of compound 3.
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Figure B55: 1H NMR spectrum (400 MHz; CDCl3) of L1.
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Figure B56: 13C NMR spectrum (100 MHz; CDCl3) of L1.
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Figure B57: 1H NMR spectrum (400 MHz; acetone-d6) of Re-L1.
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Figure B58: 13C NMR spectrum (100 MHz; acetone-d6) of Re-L1.
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Figure B59: 1H NMR spectrum (400 MHz; CD3OD) of L2.
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Figure B60: 13C NMR spectrum (100 MHz; CD3OD) of L2.
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Figure B61: 1H NMR spectrum (400 MHz; CD3CN) of Re-L2.
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Figure B62: 1H NMR spectrum (400 MHz; CD3OD) of L3.
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Figure B63: 13C NMR spectrum (100 MHz; CD3OD) of L3.
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Figure B64: 1H NMR spectrum (400 MHz; CD3OD) of Re-L3.
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Figure B65:

13

C NMR spectrum (100 MHz; CD3OD) of Re-L3.
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Figure B66: Confocal microscope images of OVCAR-8 cells incubated with Re-L1 (A,
D) Re-L2 (B, E) and Re-L3 (C, F) at a concentration of 20 µM (lEx = 458 nm, 40x
objective).
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Figure B67: Confocal microscope images (lEx = 458 nm, 100x objective) of OVCAR-8
cells incubated with Re-L1 (left), Re-L2 (middle) and Re-L3 (right). Top panel are
fluorescence images, bottom panel are fluorescence images overlaid with DIC images.
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Appendix C: Spectra of Compounds from Chapter 4

Figure C68: 1H NMR spectrum (CDCl3; 400 MHz) of compound 1.

Figure C69: 13C NMR spectrum (CDCl3; 100 MHz) of compound 1.
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Figure C70: 1H NMR spectrum (CDCl3; 400 MHz) of compound 2.

Figure C71: 13C NMR spectrum (CDCl3; 100 MHz) of compound 2.
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Figure C72: 1H NMR spectrum (CDCl3; 400 MHz) of compound 3.

Figure C73: 13C NMR spectrum (CDCl3; 100 MHz) of compound 3.
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Figure C74: 1H NMR spectrum (CDCl3; 400 MHz) of compound 4.

Figure C75: 13C NMR spectrum (CDCl3; 100 MHz) of compound 4.
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Figure C76: 1H NMR spectrum (DMSO-d6; 400 MHz) of compound 5.

Figure C77: 13C NMR spectrum (DMSO-d6; 100 MHz) of compound 5.
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Figure C78: 1H NMR spectrum (DMSO-d6; 400 MHz) of compound 6.

Figure C79: 13C NMR spectrum (DMSO-d6; 100 MHz) of compound 6.
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Figure D80: 1H NMR Spectrum (CDCl3; 400 MHz) of Compound 1.
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Figure D81: 13C NMR Spectrum (CDCl3; 100 MHz) of Compound 1.
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Figure D82: 1H NMR Spectrum (DMSO-d6; 400 MHz) of Compound 2.
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Figure D83: 13C NMR Spectrum (DMSO-d6; 100 MHz) of Compound 2.
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Figure D84: 1H NMR Spectrum (DMSO-d6; 400 MHz) of Compound 4.
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Figure D85: 13C NMR Spectrum (DMSO-d6; 100 MHz) of Compound 4.
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Figure D86: 1H NMR Spectrum (1:1 CDCl3:TFA-d; 400 MHz) of Compound 6.
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Figure D87: 13C NMR Spectrum (1:1 CDCl3:TFA-d; 100 MHz) of Compound 6.
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Figure D88: 1H NMR Spectrum of (CDCl3; 400 MHz) Compound 7.
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Figure D89: 13C NMR Spectrum (CDCl3; 100 MHz) of Compound 7.
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Figure D90: UV/Vis absorption spectra of: (A) compound 2; (B) compound 4; (C)
compound 6; and (D) compound 7 in various solvents.

Figure D91: Fluorescence emission spectra of compound 2 (20 µM) in non-polar (left) and
polar solvents (right) with 40 µM DIPEA.
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Figure D92: Fluorescence emission spectra of compound 6 (20 µM) (top) and compound
7 (20 µM) in non-polar (bottom left) and polar (bottom right) solvents.
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Table C9: Photophysical Properties of Compound 6 in Various Solvents.

e

CyH[a]

DX

2.02

2.22

4.81

8.93

25.3

33

36.6

38.3

47.2

-

361
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-

359

356

-

364
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-
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-

359

358

-

364

365

-

415
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-

425

433

-

425
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-

3528

3599

-

4326

4838

-

3943

4195

lAbs
(nm)

lEx
(nm)

lEm
(nm)
SS
(cm-1)
[a]

CHCl3 DCM[a] EtOH MeOH CH3CN[a] DMF DMSO

Insoluble

Figure D93: Fluorescence excitation and emission spectra of compound 2 in methanol
(black), upon the addition of base (blue) and upon the addition of acid (red).
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Figure D94: Fluorescence excitation and emission spectra of the Zn(II) complexes of:
(A) compound 1; (B) compound 2; (C) compound 4; (D) compound 6; and (E) compound
7 in methanol.
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